clostridium
difficil
main
caus
nosocomi
diarrhoea
develop
countri
incid
diseas
due
bacterium
increas
recent
year
sever
outbreak
includ
strain
associ
increas
sever
number
antibiot
clinic
treatment
clostridium
difficil
infect
antimicrobi
peptid
offer
promis
novel
agent
develop
resist
microb
may
develop
novel
approach
combin
deliveri
antimicrobi
peptid
agent
protect
host
epithelia
treatment
clostridium
difficil
infect
diseas
mcfarland
l
v
updat
chang
epidemiolog
clostridium
associ
diseas
nat
clin
pract
gastroenterol
hepatol
bricker
e
garg
r
nelson
r
loza
novak
hansen
j
antibiot
treatment
clostridium
diarrhea
adult
cochran
databas
syst
rev
hancock
r
e
sahl
h
g
antimicrobi
peptid
new
infect
therapeut
strategi
nat
biotechnol
total
chemic
synthesi
use
prepar
seri
uniqu
analogu
proteas
pr
systemat
substitut
residu
tip
mobil
flap
residu
domain
protein
homodim
symmetr
asymmetr
fashion
substitut
although
region
distant
catalyt
aspart
led
case
substanti
reduct
catalyt
activ
contrast
chemic
synthes
amino
acid
residu
coval
dimer
protein
one
flap
flap
enzym
activ
gain
insight
molecular
detail
phenomena
appli
varieti
biophys
method
includ
nmr
spectroscopi
well
crystallographi
appropri
enzymat
assay
nmr
relax
experi
label
protein
measur
analogu
reveal
pr
nearli
flap
mobil
time
scale
wherea
pr
much
rigid
flap
time
scale
molecular
dynam
simul
demonstr
asymmetr
combin
flap
symmetr
dd
uniqu
stabil
conform
state
catalyt
residu
nucleophil
water
molecul
prearrang
catalysi
result
obtain
also
confirm
viral
proteas
monomer
aspart
proteas
share
intrins
asymmetr
chemic
mechan
homodimer
coil
coil
fold
acid
condit
design
design
use
start
coil
coil
oncoprotein
coil
coil
contain
natur
occur
glutam
acid
hydrophob
core
modul
proton
state
could
potenti
regul
coil
coil
format
base
electrostat
destabil
hydrophob
core
buri
charg
howev
denatur
peptid
reveal
signific
chang
thermal
stabil
wide
ph
rang
behavior
purport
aris
stabil
salt
bride
compens
buri
neg
charg
center
induc
ph
respons
behavior
firstli
mutat
unmask
effect
second
layer
mutat
glu
magnifi
charg
repuls
inhibit
coil
coil
format
detail
thermodynam
auc
orient
analys
show
delet
salt
bridg
significantli
compromis
thermal
stabil
abil
protein
adopt
coil
coil
lost
mixtur
parallel
coil
coil
realiz
howev
adopt
homodimer
coil
coil
manner
margin
decreas
thermal
stabil
electron
vibrat
circular
dichroism
often
use
determin
secondari
structur
protein
secondari
structur
uniqu
spectrum
order
determin
spectral
featur
polypeptid
known
adopt
desir
conform
along
entir
length
studi
ideal
littl
known
vibrat
circular
dichroism
spectroscop
featur
studi
use
decapeptid
yydpetgtwi
form
stabl
stabil
intramolecular
weakli
polar
interact
hydrogen
bond
synthes
solid
phase
peptid
synthesi
protect
amino
acid
purif
revers
phase
hplc
column
found
adopt
two
conform
shown
far
much
larger
polypeptid
structur
aqueou
organ
solvent
examin
use
electron
vibrat
circular
dichroism
spectroscopi
presenc
confirm
ecd
uniqu
vcd
signal
observ
molecular
dynam
simul
use
correl
conform
featur
cd
spectra
aqueou
organ
solvent
work
support
grant
carpent
endow
chair
biochemistri
creighton
univers
interact
defin
modul
biomolecular
structur
function
dynam
mani
protein
secondari
structur
intim
interact
exist
adjac
carbonyl
group
amid
bond
short
contact
contribut
energet
protein
conform
stabil
well
interact
understand
natur
crucial
intimaci
carbonyl
group
could
aris
interact
electron
deloc
last
put
origin
reminisc
trajectori
involv
deloc
lone
pair
n
oxygen
peptid
bond
antibond
orbit
p
carbonyl
group
cioi
subsequ
peptid
bond
instal
isoster
chemic
substitu
peptid
model
system
use
nmr
spectroscopi
diffract
analysi
ab
initio
calcul
analyz
consequ
intim
interact
adjac
carbonyl
group
shown
aris
primarili
electron
deloc
addit
comput
analysi
nhme
peptid
model
system
suggest
widespread
electron
deloc
allow
region
ramachandran
plot
find
implic
organ
biolog
medicin
chemistri
critic
analysi
crystallograph
structur
indic
protein
helic
popul
singl
smoothli
peak
distribut
rather
weight
bimod
distribut
expect
mix
popul
helic
popul
center
f
coordin
intermedi
classic
paramet
ideal
data
contradict
prevail
dogma
helic
protein
exist
near
one
classic
ideal
helic
configur
protein
databank
pdb
shown
manifest
clear
bia
toward
supposedli
ideal
helic
nomin
resolut
greater
structur
model
insuffici
constrain
experiment
electron
densiti
new
model
helic
protein
account
contribut
share
bifurc
hydrogen
bond
evolv
straightforward
interpret
crystallograph
data
physicochem
constraint
new
molten
helic
model
unifi
experiment
observ
concept
protein
helix
stabl
secondari
structur
sampl
conform
space
singl
smooth
potenti
well
locat
classic
coordin
energi
surfac
togeth
observ
regard
helic
model
suggest
simpl
improv
backbon
potenti
molecular
mechan
paramet
particularli
electrostat
score
function
protein
fold
helic
peptidomimet
design
bia
abund
structur
seen
crystal
structur
pdb
sever
compromis
structur
databas
hypothes
aris
form
use
monopol
electrostat
model
program
detail
statist
analysi
impact
crystallograph
resolut
protein
secondari
structur
suggest
well
thorough
comparison
impact
quantum
mechan
approxim
methodolog
potenti
surfac
bifurc
hydrogen
bond
anticip
base
recent
analys
helic
hydrogen
bond
crystal
structur
protein
pdb
detail
secondari
structur
nomin
resolut
structur
model
protein
may
necessari
peptid
becom
popular
model
system
beta
sheet
structur
protein
relianc
high
propens
revers
turn
limit
use
model
behavior
natur
beta
sheet
flexibl
loop
larg
contact
order
strand
herein
report
class
homodimer
turnless
beta
sheet
link
central
cystin
residu
construct
rang
residu
per
strand
adopt
structur
contain
unnatur
amino
acid
though
betasheet
structur
observ
number
divers
homodimer
sequenc
stabl
tm
c
employ
specif
beta
cap
motif
motif
take
form
cap
end
beta
sheet
construct
provid
use
minim
system
studi
beta
sheet
structur
serv
illustr
potenc
beta
cap
motif
superflu
nucleat
backbon
turn
sequenc
design
enhanc
stabil
challeng
problem
thermal
stabil
synthet
chimer
analog
analyz
use
molecular
simul
circular
dichroism
differenti
scan
calorimetri
nmr
experiment
melt
curv
determin
use
cd
dsc
melt
curv
also
calcul
explicit
solvent
molecular
dynam
simul
simul
result
show
exhibit
weak
cooper
alpha
helix
beta
hairpin
beta
hairpin
rel
unstabl
format
necessari
format
hydrophob
core
fold
experiment
melt
curv
resembl
slowli
unfold
helix
instead
folder
weak
stabil
support
nmr
measur
shown
polypeptid
rapidli
immobil
glass
substrat
mean
thiol
catalyz
nativ
chemic
ligat
ncl
biopolymerspeptidesci
aim
present
contribut
build
long
molecul
glass
surfac
biosensor
acid
kda
peg
polyethylen
glycol
attach
glass
surfac
extend
kda
oligom
purpos
first
boc
synthes
coupl
cy
modifi
glass
surfac
ncl
reaction
follow
surfac
plasmon
reson
spr
second
peg
unit
attach
procedur
dilut
aqueou
hcl
deprotect
boc
protect
first
unit
order
measur
length
attach
construct
surfac
probe
atom
forc
microscopi
afm
purpos
peg
prepar
coupl
either
instead
first
peg
second
peg
thu
give
opportun
molecular
recognit
conjunct
afm
cantilev
coat
biotinyl
bsa
streptavidin
afm
configur
mode
surfac
probe
peg
length
measur
pull
perpendicularli
pull
forc
record
length
ruptur
point
close
theoret
peg
length
ruptur
forc
similar
bond
confirm
correct
tether
immobil
length
function
cyclotid
peptid
incorpor
uniqu
structur
motif
compris
three
disulfid
bond
circular
backbon
engend
particularli
high
degre
stabil
enzymat
chemic
assault
divid
two
major
subfamili
term
bracelet
cyclotid
current
largest
known
famili
circular
protein
rang
intrins
activ
identifi
includ
haemolyt
antifoul
insecticid
activ
major
question
regard
biolog
cyclotid
remain
unansw
cyclotid
exert
biolog
effect
plasma
membran
first
cellular
barrier
interact
cyclotid
membran
seem
biolog
activ
current
studi
examin
membran
interact
cyclotid
two
major
subfamili
along
natur
hybrid
two
famili
fluoresc
spectroscopi
surfac
plasmon
reson
confoc
microscopi
optic
densiti
use
analys
peptid
model
membran
cyclotid
studi
show
prefer
membran
contain
phosphatidylethanolamin
phospholipid
wherea
phospholipid
affect
membran
bind
extens
presenc
cholesterol
modul
membran
fluiditi
alter
membran
prefer
result
clearli
show
cyclotid
prefer
rigid
domain
membran
raft
domain
bind
mainli
govern
hydrophob
rather
electrostat
interact
cyclotid
belong
bracelet
famili
abl
disintegr
membran
bilay
wherea
peptid
appear
form
pore
without
membran
destruct
overal
shown
even
similar
membran
select
differ
cyclotid
differ
effect
membran
stabil
explain
divers
famili
also
divers
activ
alzheim
diseas
ad
patholog
character
two
distinct
lesion
neurofibrillari
tangl
compris
hyperphosphoryl
microtubul
associ
tau
protein
neurit
plaqu
compris
princip
amyloid
plaqu
format
thought
key
develop
ad
much
effort
spent
studi
aggreg
attempt
remov
prevent
format
plaqu
physiolog
role
much
less
well
understood
recent
shown
bind
specif
dna
sequenc
suggest
possibl
role
transcript
factor
societi
neurosci
meet
better
understand
physiolog
role
studi
uptak
cultur
cell
oxid
stress
respons
oxid
stress
local
nuclei
portion
viabl
cell
nearli
dead
cell
littl
nuclear
local
observ
unstress
cell
pattern
nuclear
label
suggest
role
oxid
death
cascad
import
player
ad
result
provid
clue
physiolog
role
toxic
seen
ad
protein
tyrosin
phosphatas
particip
signal
event
interact
tandem
domain
variou
activ
receptor
bind
specif
domain
previous
determin
combinatori
librari
approach
found
domain
could
recogn
four
distinct
class
bind
motif
studi
structur
class
iv
motif
vipyfvp
bound
domain
determin
reveal
noncanon
peptid
protein
bind
mode
bind
mode
confirm
solut
phase
hsqc
hsqc
nmr
experi
app
cleav
enzym
bace
enzym
involv
product
implic
format
amyloid
plaqu
within
alzheim
diseas
brain
perform
primari
cleavag
amyloid
precursor
protein
app
pathway
bace
serv
favour
therapeut
target
app
implic
modul
activ
numer
known
biolog
synthet
substrat
may
also
play
role
mechan
regul
cleavag
activ
matur
bace
remain
unclear
studi
explor
role
differ
sequenc
domain
within
app
modul
bace
activ
specif
utilis
bace
cleavag
domain
app
numer
substrat
peptid
scaffold
form
superset
bace
substrat
analogu
gener
via
seri
truncat
extens
termini
cap
residu
substitut
side
chain
modif
via
peptid
synthesi
quench
fluoresc
substrat
bace
assay
conjunct
lcm
analysi
use
investig
cleavag
suscept
inhibit
potenc
competit
condit
defin
subset
peptid
function
modul
bace
activ
identifi
inhibitori
stimulatori
structur
motif
result
provid
insight
possibl
modulatori
role
app
bace
function
vivo
avenu
explor
novel
bace
inhibitor
design
histon
deacetylas
hdac
enzym
repress
gene
transcript
remov
acetyl
group
histon
aberr
recruit
express
hdac
correl
tumorigenesi
process
provid
rational
use
hdac
inhibitor
treat
cancer
among
mani
compound
preclin
investig
bicycl
depsipeptid
consid
potent
hdac
inhibitor
vitro
vivo
howev
synthet
challeng
made
sar
studi
difficult
would
facilit
understand
structur
requir
natur
product
herein
report
novel
analogu
synthet
challeng
unit
acid
modifi
simpl
isoster
substitut
modif
alter
backbon
conform
enabl
facil
product
larg
number
analogu
high
synthet
effici
develop
solidphas
strategi
allow
rapid
synthesi
high
overal
yield
puriti
compound
construct
explor
posit
origin
structur
varieti
side
chain
function
group
examin
anticanc
activ
prepar
analogu
evalu
variou
cancer
cell
new
potent
analogu
identifi
valu
nm
eukaryot
genom
organ
period
wrap
dna
doubl
helix
around
histon
octam
form
nucleosom
dna
region
nucleosom
vital
interfac
dna
doubl
helix
histon
octam
dynam
acetyl
histon
lysin
buri
beneath
dna
region
play
import
role
dna
repair
transcript
regul
present
synthesi
histon
acetyl
ly
sequenti
nativ
chemic
ligat
three
peptid
segment
nucleosom
reconstitut
synthet
chemic
modifi
along
dna
recombin
histon
biochem
biophys
studi
result
modifi
nucleosom
allow
direct
character
effect
nucleosom
structur
dynam
figur
nucleosid
analogu
conform
restrict
modifi
nucleosid
orient
c
group
around
c
bond
differ
found
unmodifi
exhibit
high
rna
affin
base
shown
promis
properti
antisens
anion
natur
backbon
oligonucleotid
repres
major
challeng
cellular
uptak
reason
introduct
lipophil
substitu
modifi
nucleosid
could
improv
cellular
uptak
modifi
oligonucleotid
addit
modif
bicycl
core
could
induc
correct
misalign
torsion
angl
result
higher
rna
affin
new
thymidin
carri
benzyl
substitu
synthes
use
select
nucleosid
structur
determin
crystallographi
modifi
nucleosid
incorpor
oligonucleotid
solid
phase
synthesi
use
phosphoramidit
chemistri
stabil
dna
duplex
hybrid
duplex
contain
modifi
nucleotid
determin
experi
shape
duplex
analyz
base
pair
select
modifi
oligonucleotid
determin
measur
stabil
dna
duplex
contain
mismatch
base
opposit
modifi
nucleotid
final
oligonucleotid
transfect
hela
cell
cell
analyz
fluoresc
tarkoy
leumann
c
angew
chem
int
ed
eng
tarkoy
bolli
leumann
c
helv
chim
acta
steffen
r
leumann
c
helv
chim
acta
pallan
p
ittig
heroux
wawrzak
z
leumann
c
egli
chem
commun
steffen
r
leumann
c
j
amer
chem
soc
renneberg
mouliong
e
reber
u
schumperli
leumann
c
nucleic
acid
re
ittig
renneberg
schumperli
leumann
c
nucleic
acid
re
luisier
leumann
c
chembiochem
comput
approach
use
virtual
screen
combin
consensu
score
reveal
compound
inhibit
function
phop
respons
regul
disrupt
format
activ
dimer
state
phop
regulatori
receiv
phoqphop
signal
transduct
system
sens
respond
extracellular
level
control
transcript
level
key
virul
gene
salmonella
typhimurium
well
number
pathogen
speci
includ
yersinia
pesti
caus
pathogen
plagu
inact
monomer
state
phop
activ
via
phosphoryl
phoq
sensor
histidin
kinas
low
extracellular
level
phosphoryl
lead
format
activ
dimer
state
bind
dna
promot
compound
bind
surfac
dimer
interfac
disrupt
abil
importantli
interfer
function
transcript
factor
regul
virul
experiment
method
includ
electrophoret
assay
gel
filtrat
chromatographi
use
test
predict
comput
approach
confirm
mechan
action
predict
inhibitor
studi
serv
target
dimer
interfac
respons
regul
inhibit
function
modul
gene
regul
express
virul
increas
resist
pathogen
bacteria
current
antibiot
success
strategi
suggest
target
signal
transduct
system
promis
approach
develop
novel
antibiot
cyclic
lipodepsipeptid
divers
class
natur
product
signific
pharmacotherapeut
potenti
daptomycin
cyclic
lipodepsipeptid
decadepsipeptid
core
ring
produc
ferment
product
streptomyc
roseosporu
daptomycin
effect
bactericid
agent
resist
gramposit
bacteria
mrsa
success
synthesi
variou
cyclic
lipodepsipeptid
daptomycin
analogu
achiev
use
glutam
acid
place
acid
posit
cyclic
core
structur
kynurenin
residu
utilis
depsipeptid
bond
format
substitut
tryptophan
valin
isoleucin
macrolactamis
took
place
trpvalil
group
synthesi
protect
acid
buildingblock
also
accomplish
via
enzymat
resolut
racem
acid
ester
success
synthesi
daptomycin
analogu
amino
acid
demonstr
feasibl
total
spp
daptomycin
natur
effector
innat
immun
host
defens
peptid
hdp
exhibit
rapid
kill
broad
spectrum
activ
bacteria
fungi
virus
hdp
thu
inspir
varieti
design
antimicrobi
therapeut
recent
other
demonstr
simpl
combin
arginin
r
trptophan
w
side
chain
constitut
pharmacophor
one
class
hdp
base
result
employ
two
strategi
aim
identifi
potent
antimicrobi
agent
ultim
therapeut
treatment
mdr
bacteri
infect
first
deriv
applic
principl
multival
creat
antimicrobi
agent
use
varieti
scaffold
link
short
rw
peptid
afford
multival
construct
differ
topolog
second
strategi
design
screen
sever
combinatori
librari
base
scaffold
mimic
hydrophob
charg
pattern
detect
pharmocophor
metion
set
compound
identifi
strategi
potent
antimicrobi
activ
low
hemolyt
activ
provid
set
new
antimicrobi
lead
open
possibl
rout
novel
antimicrobi
pharmaceut
properti
natur
peptid
due
grow
increas
antibiot
resist
antimicrobi
peptid
amp
becom
import
candid
potenti
therapeut
agent
two
uniqu
featur
net
posit
charg
greater
owe
excess
basic
amino
acid
ly
arg
acid
amino
acid
asp
glu
amphipath
natur
face
polar
face
main
target
cell
membran
microorgan
lead
compound
peptid
show
singl
valin
lysin
substitut
compar
parent
peptid
center
face
dramat
reduc
toxic
increas
therapeut
index
systemat
substitut
posit
charg
residu
polar
face
give
net
posit
charg
well
chang
rel
locat
charg
residu
maintain
ident
face
analog
evalu
peptid
analog
antimicrobi
activ
six
clinic
strain
pseudomona
aeruginosa
hemolyt
activ
human
red
blood
cell
increas
net
posit
charg
vari
locat
charg
residu
dramat
effect
antimicrobi
activ
result
therapeut
index
last
two
decad
incid
human
fungal
infect
increas
mainli
immunocompromis
patient
addit
mani
microorgan
shown
resist
common
antibiot
therefor
altern
antimicrobi
agent
found
natur
antimicrobi
peptid
optim
candid
fight
resist
microorgan
activ
recent
report
endogen
linear
peptid
particularli
tripeptid
potent
antimicrobi
activ
two
repres
pathogen
staphylococcu
aureu
c
albican
inde
candidacid
effect
link
increas
intracellular
camp
calbican
possibl
hypothes
interact
peptid
yeast
isoform
melanocortin
receptor
previou
studi
allow
obtain
msh
origin
chang
sequenc
analog
show
potent
candidacid
activ
becam
lead
compound
improv
antifung
activ
residu
glycin
lead
compound
replac
natur
unnatur
amino
acid
new
potent
antifung
compound
identifi
wide
rang
antimicrobi
peptid
amp
natur
activ
peptid
usual
depend
sever
paramet
sequenc
size
degre
structur
format
hydrophob
amphipath
work
plan
analysi
paramet
order
design
potent
ampcandid
although
paramet
infleuenc
activ
directli
correlatedamp
due
neg
charg
usual
anticanc
activ
work
focu
group
peptid
choos
aurein
design
target
peptid
design
peptid
synthesis
analys
conform
mic
test
compar
aurein
protein
peptid
grp
found
anim
plant
littl
known
chemic
synthesi
structur
relationship
mode
action
studi
shepherin
shepi
antimicrobi
grp
gli
analogu
stepwis
synthesi
spectra
grow
indic
shep
prone
aggreg
among
analogu
studi
amid
shep
ia
shep
shep
show
attract
activ
shep
c
albican
strain
anticandid
activ
shep
ia
shep
shep
inhibit
high
salt
concentr
solut
significantli
enhanc
solut
mic
shep
ia
kill
c
albican
min
caus
low
hemolysi
phosphat
buffer
salin
isoton
glucos
phosphat
buffer
confoc
microscopi
flow
cytometri
analys
reveal
shep
ia
modifi
carboxyfluorescein
ia
rapidli
intern
c
albican
cell
process
energi
affect
high
salt
concentr
altogeth
result
suggest
shep
mimic
fungicid
activ
shep
ii
shep
ia
intracellular
target
intern
fungal
cell
via
endocitosi
support
fapesp
cnpq
temporin
antimicrobi
peptid
amp
isol
skin
rana
temporaria
short
linear
residu
long
peptid
net
charg
posit
amid
ctermin
get
insight
mechan
action
biolog
activ
compound
investig
two
member
famili
temporin
l
tl
temporin
ta
first
preferenti
activ
bacteri
strain
nt
haemolyt
activ
second
highest
activ
among
temporin
show
haemolyt
activ
concentr
requir
kill
bacteria
investig
preferenti
conform
tl
ta
sd
dpc
solut
base
nmr
cd
result
design
synthes
new
ta
tl
analogu
call
understand
exact
mechan
action
addit
synthes
compound
contain
analogu
defin
structur
characterist
design
featur
peptid
gomesin
gm
potent
antimicrobi
peptid
molecul
two
disulfid
bridg
adopt
structur
gm
non
activ
linear
analogu
synthes
methodolog
show
result
obtain
optic
fluoresc
microscopi
giant
unilamellar
vesicl
guv
compos
mixtur
neutral
popc
neg
charg
popg
lipid
two
differ
setup
use
first
observ
effect
inject
peptid
solut
micropipett
place
vicin
guv
result
interact
guv
burst
suddenli
stabl
pore
hardli
ever
observ
control
absenc
peptid
guv
never
spontan
disrupt
fact
lead
us
specul
gomesin
disrupt
membran
via
carpet
mode
inject
fluoresc
label
peptid
show
gm
first
accumul
vesicl
surfac
domain
form
eventu
vesicl
burst
second
setup
guv
solut
mix
increas
concentr
peptid
quantifi
lytic
action
guv
differ
composit
observ
effect
lytic
activ
around
gomesin
gm
result
conclud
peptid
strongli
interact
phospholipid
vesicl
induc
leakag
content
surfac
manner
support
fapesp
cnpq
fadaunifesp
fusaricidin
cyclic
lipodepsipeptid
origin
isol
bacillu
polymyxa
strain
exhibit
promis
activ
variou
kind
fungi
bacteria
includ
aureu
order
elucid
structur
basi
antibacteri
activ
synthes
fusaricidin
analogu
differ
lipid
tail
part
librari
use
standard
fmoc
methodolog
librari
screen
assay
reveal
lipophyl
tail
amino
acid
involv
creation
ester
bond
crucial
peptid
antibacteri
activ
complet
loss
antibacteri
activ
obtain
depsipeptid
without
lipid
tail
peptid
cycliz
via
ly
side
chain
amino
group
instead
hydroxyl
group
found
natur
product
exist
research
show
amid
analog
pleurocidin
activ
antibacteri
agent
nativ
acid
evid
suggest
amphipath
structur
requir
antibacteri
activ
pleurocidin
assum
amphipath
conform
similar
antimicrobi
peptid
amp
presenc
hexafluoroisopropanol
although
exact
mechan
antimicrobi
peptid
kill
bacteri
cell
still
unknown
believ
cation
charg
peptid
initi
attract
neg
charg
bacteri
surfac
lipid
hypothesi
specif
alter
sequenc
amino
acid
nativ
pleurocidin
increas
antimicrobi
activ
test
effect
addit
tryptophan
pleurocidin
amid
develop
bioassay
evalu
effect
amp
analog
four
divers
type
pathogen
bacteria
comput
approach
use
virtual
screen
combin
consensu
score
reveal
compound
inhibit
function
phop
respons
regul
disrupt
format
activ
dimer
state
phop
regulatori
receiv
phoqphop
signal
transduct
system
sens
respond
extracellular
level
control
transcript
level
key
virul
gene
salmonella
typhimurium
well
number
pathogen
speci
includ
yersinia
pesti
caus
pathogen
plagu
monomer
state
phop
activ
via
phosphoryl
phoq
sensor
histidin
kinas
low
extracellular
level
phosphoryl
lead
format
activ
phop
dimer
bind
dna
promot
compound
bind
surfac
dimer
interfac
disrupt
abil
importantli
interfer
role
transcript
factor
regul
virul
experiment
method
includ
electrophoret
assay
chromatographi
use
test
predict
comput
approach
confirm
mechan
action
predict
inhibitor
studi
serv
target
dimer
interfac
respons
regul
inhibit
function
modul
gene
regul
express
virul
increas
resist
pathogen
bacteria
current
antibiot
success
strategi
suggest
target
signal
transduct
promis
approach
develop
novel
antibiot
periodont
diseas
inflammatori
diseas
predominantli
affect
gum
link
onset
sever
system
diseas
diseas
caus
format
accumul
bacteri
biofilm
pocket
particular
presenc
porphyromona
gingivali
p
gingivali
asaccharolyt
oblig
anaerob
interact
specif
bacteri
speci
orali
group
streptococci
success
colon
oral
caviti
interact
bacteria
mediat
interact
occur
minor
fimbrial
protein
p
gingivali
sspb
adher
region
bar
antigen
iii
protein
eg
sspb
express
streptococci
studi
shown
inhibit
use
synthet
peptid
base
bar
amino
acid
motif
nitvk
essenti
interact
current
studi
expand
interact
interfac
show
eukaryot
nuclear
receptor
motif
vxxll
also
involv
facilit
bar
interact
maintain
amphipath
region
import
bind
bar
addit
posit
charg
lysin
residu
flank
vxxll
shown
contribut
interact
vxxll
nitvk
motif
conserv
among
orali
streptococci
sequenc
diverg
antigen
iii
protein
express
streptococci
interact
p
gingivali
comparison
also
identifi
conserv
prolin
residu
upstream
vxxll
substitut
result
loss
peptid
inhibitori
activ
suggest
may
also
play
import
structur
role
interact
bar
togeth
studi
defin
interact
may
drive
initi
colon
oral
caviti
p
gingivali
may
facilit
develop
target
therapeut
prevent
colon
small
synthet
conotoxin
develop
therapeut
neuropath
pain
shown
induc
analgesia
rat
model
human
neuropath
pain
report
target
nachr
low
nm
potenc
conduct
mutat
studi
replac
individu
residu
either
alanin
lysin
aspart
acid
except
highli
conserv
cystein
two
key
posit
identifi
posit
posit
mutat
led
signific
increas
potenc
nachr
subsequ
second
gener
analogu
synthesis
mutat
posit
shown
equal
potent
nachr
potent
mutant
also
test
human
rat
hybrid
clone
potenti
chang
select
profil
potent
mutant
also
test
nachr
subtyp
name
second
gener
analogu
select
analogu
exclus
select
nachr
subtyp
screen
studi
shown
potenc
improv
whilst
maintain
select
strateg
substitut
key
posit
identifi
mutat
studi
overal
mutat
studi
provid
great
foundat
design
synthesi
novel
conotoxin
mark
improv
potenc
select
toward
nachr
report
novel
coronaviru
caus
agent
sever
acut
respiratori
syndrom
sar
sar
epidem
result
infect
result
death
sever
attempt
made
develop
compound
inhibit
howev
effect
therapi
avail
far
henc
still
matter
necess
develop
new
potent
compound
case
diseas
herein
disclos
design
synthesi
activ
seri
trifluoromethyl
benzothiazolyl
thiazolyl
peptid
compound
proteas
inhibitor
three
candid
encourag
result
develop
new
compound
sydn
hayashi
sharma
v
k
hamada
bacha
u
barrila
j
freir
e
kiso
tetrahedron
bacha
u
barrila
j
gabelli
b
kiso
amzel
l
freir
e
chem
biol
drug
de
last
decad
success
use
oboc
combinatori
librari
method
identifi
ligand
target
cancer
cell
surfac
molecul
abl
demonstr
ligand
use
effect
optic
radioimag
agent
cancer
recent
develop
obtc
combinatori
librari
method
facilit
discoveri
ligand
affect
cell
function
interact
specif
receptor
cell
surfac
new
method
use
topograph
segreg
bilay
bead
method
gener
chemic
librari
bead
two
distinct
chemic
molecul
display
bead
surfac
code
tag
bead
interior
one
molecul
could
high
affin
integrin
ligand
bind
strongli
cancer
cell
molecul
eg
peptid
lipopeptid
howev
total
random
encod
code
tag
bead
interior
uniqu
bead
incub
bead
display
random
peptid
lipopeptid
live
lymphoma
cell
lymphoma
cell
line
minut
major
bead
coat
ad
cell
upon
ad
lasp
rhodamin
hour
later
detect
rare
bead
cover
entir
apoptot
cell
indic
second
ligand
display
bead
surfac
capac
induc
apoptosi
lymphoid
cancer
cell
work
current
underway
evalu
proapoptot
mechan
molecul
lam
ks
et
al
new
type
synthet
peptid
librari
identifi
bind
activ
natur
p
aina
oh
et
al
combinatori
chemistri
peptid
mol
pharm
p
li
p
et
al
combinatori
chemistri
identifi
peptidomimet
integrin
vivo
tumor
imag
natur
chem
biol
p
liu
r
et
al
novel
encod
system
peptidomimet
small
molecul
combinatori
librari
j
chem
soc
p
screen
oboc
librari
provid
power
method
rapid
identif
activ
compound
biolog
target
howev
screen
suscept
interfer
nonspecif
bind
result
bias
screen
fals
posit
work
found
major
sourc
nonspecif
bind
deriv
high
ligand
load
librari
bead
permit
macromolecular
target
eg
protein
simultan
interact
multipl
ligand
bead
surfac
circumv
problem
synthes
phosphotyrosyl
py
peptid
librari
spatial
segreg
tentagel
microbead
featur
reduc
peptid
load
bead
surfac
normal
peptid
load
bead
interior
librari
screen
src
homolog
domain
includ
csk
fyn
slap
specif
recognit
motif
success
identifi
domain
contrast
domain
screen
control
librari
contain
unalt
high
ligand
load
bead
surfac
six
exhibit
vari
degre
sequenc
bias
reduct
ligand
load
bead
surfac
repres
simpl
effect
strategi
larg
elimin
interfer
nonspecif
bind
preserv
suffici
amount
materi
bead
interior
compound
identif
find
expand
util
oboc
librari
biomed
research
oboc
combinatori
method
compound
construct
bead
resin
via
synthesi
multipl
copi
librari
compound
display
bead
librari
rapidli
screen
elisa
fluoresc
radiometr
bind
assay
probe
power
tool
oboc
screen
util
greatli
limit
intrins
fluoresc
mani
commonli
use
solid
support
eg
tentagel
tg
resin
residu
coupl
reagent
librari
compound
overcom
problem
topolog
partit
tg
resin
thin
outer
layer
unprotect
inner
core
inner
core
derivat
follow
random
peptid
librari
construct
spectral
scan
confoc
microscop
show
dramat
decreas
autofluoresc
blank
bead
oboc
peptid
librari
across
broad
rang
optic
spectrum
quench
capac
visual
fluoresc
micrograph
bead
sampl
use
biotinstreptavidin
model
ligandreceptor
system
demonstr
mark
increas
visibl
multipl
commerci
avail
fluoresc
probe
bind
quench
bead
increas
feasibl
use
robust
effici
bead
sort
platform
known
data
show
use
intern
quencher
greatli
enhanc
compat
applic
oboc
combinatori
screen
isomeras
play
signific
role
regul
alter
conform
thu
functionst
target
phosphoprotein
recent
studi
suggest
potenti
target
anticanc
drug
design
dphosphoserin
contain
cyclic
peptid
librari
built
base
structur
substrat
specif
screen
librari
peptid
select
individu
synthes
test
bind
peptid
shown
bind
kd
rang
isotherm
titrat
calorimetri
inhibit
potenc
confirm
vitro
enzymat
assay
test
whether
inhibitor
activ
cell
examin
effect
one
inhibitor
protein
level
two
known
target
pml
smrt
data
show
treatment
hela
cell
inhibitor
lead
increas
protein
level
pml
smrt
postsynapt
largezona
pdz
domain
bind
free
target
protein
mediat
protein
interact
display
either
uniqu
overlap
specif
buz
binder
ubiquitin
domain
bind
free
ubiquitin
therefor
help
mediat
signal
event
brct
domain
interact
varieti
protein
involv
dna
damag
respons
shown
associ
mani
protein
phosphoryl
depend
manner
oboc
combinatori
librari
approach
allow
determin
individu
bind
sequenc
protein
interest
compil
analyz
determin
specif
particular
protein
domain
oboc
librari
use
defin
sequenc
specif
pdz
domain
tiam
tiam
buz
domain
brct
domain
ptip
acid
amino
acid
replac
nitrogen
atom
lone
pair
repuls
adjac
nitrogen
atom
acid
residu
suggest
induc
turn
conform
observ
diffract
nmr
spectroscopi
comput
analysi
analog
hexapeptid
exhibit
dual
affin
toward
receptor
synthes
use
chemistri
protocol
make
librariesi
certain
analog
exhibit
select
receptor
present
describ
synthesi
bind
affin
valu
receptor
well
vitro
antiangiogen
properti
best
analogsiboeglin
lubel
wd
jcombchem
cyclic
peptid
potenti
mimic
select
process
evolv
enzym
linear
peptid
contain
moieti
establish
catalyst
kinet
resolut
certain
secondari
alcohol
howev
cyclic
peptid
moieti
studi
catalyt
reaction
work
new
type
cyclic
peptid
develop
acyl
transfer
catalyst
cyclic
peptid
librari
million
peptid
contain
five
random
posit
histidin
synthes
resin
fluoresc
ph
sensor
correspond
linear
peptid
also
employ
librari
screen
sever
acyl
reaction
select
brightest
bead
librari
identifi
activ
catalyst
resynthesi
cyclic
peptid
carri
preliminari
result
show
select
cyclic
peptid
catalyz
acyl
reaction
respons
peptid
consist
amphiphil
fuse
helic
domain
capabl
form
coil
coil
design
design
allow
studi
synergist
contribut
materi
format
multipl
distinct
motif
within
peptid
fold
domain
helic
trigger
ph
temperatur
cd
ftir
employ
probe
chang
secondari
conform
low
temperatur
predomin
high
temperatur
aggreg
state
coil
coil
append
investig
use
auc
fusion
peptid
form
physic
crosslink
hydrogel
fibrillar
nanostructur
fibril
dimens
measur
tem
elucid
underli
mechan
rheolog
studi
reveal
upon
heat
wt
peptid
solut
ph
viscoelast
gel
form
rich
fibrillar
network
cool
room
temperatur
exhibit
increas
mechan
rigid
concomit
refold
helic
domain
system
provid
uniqu
bottom
approach
creat
object
smaller
fragment
system
particular
interest
field
regen
medicin
system
success
use
scaffold
cellular
prolifer
specif
collagen
base
scaffold
particularli
desir
major
compon
extra
cellular
matrix
date
sever
group
develop
collagen
fiber
incorpor
varieti
sticki
end
grow
linear
mechan
howev
system
gener
similarli
shape
structur
provid
control
architectur
consequ
success
design
synthes
three
peptid
byp
byp
collagen
mimet
peptid
capabl
assembl
radial
mechan
varieti
uniqu
structur
fiber
disk
hollow
sphere
may
provid
enhanc
biolog
properti
current
collagen
base
scaffold
collagen
fiber
import
compon
skin
tendon
cartilag
blood
vessel
control
collagen
upon
environment
condit
essenti
featur
biomateri
applic
electrostat
interact
one
popular
strategi
promot
collagen
peptid
herein
disclos
collagen
peptid
use
posit
neg
charg
collagen
peptid
posit
neg
charg
introduc
pog
peptid
incorpor
hydroxyprolin
carboxyl
amin
function
collagen
peptid
display
electron
charg
expos
environment
condit
stabil
tripl
helix
neutral
ph
success
show
control
multipl
homotrim
upon
ph
condit
electrostat
interact
display
charg
peptid
design
distinct
previou
research
thermal
unfold
collagen
peptid
necessari
process
promot
self
assembl
peptid
peptid
form
cone
shape
structur
confirm
dynam
light
scatter
atom
forc
microscopi
anticip
design
self
assembl
collagen
peptid
offer
new
possibl
strategi
variou
collagen
biomateri
applic
hierarch
assembl
nanoscal
build
block
function
materi
power
strategi
design
devic
regen
medicin
tissu
engin
essenti
featur
success
tissu
engin
instanc
includ
control
scaffold
morpholog
nm
micro
scale
along
tempor
spatial
releas
specif
growth
factor
promot
tissu
growth
repair
herein
design
synthes
peptid
compos
core
flank
metal
bind
moieti
nitrilotriacet
acid
nta
unit
report
peptid
rapidli
revers
assembl
presenc
metal
ion
form
microflorett
reproduc
size
shape
addit
demonstr
unsatisfi
metalligand
exist
surfac
within
microflorett
may
easili
modifi
function
molecul
two
distinct
fluoresc
protein
use
demonstr
protein
could
incorpor
within
structur
spatial
control
critic
use
biomed
applic
abil
associ
mammalian
cell
show
microflorett
capabl
avidli
bind
variou
adher
suspend
cell
unpreced
microscop
structur
offer
opportun
mani
area
includ
tissu
engin
regener
articular
cartilag
play
import
role
bear
mechan
load
shear
forc
joint
due
avascular
natur
articular
cartilag
limit
capac
repair
make
injuri
difficult
treat
current
therapi
joint
replac
autolog
cell
implant
often
invas
lead
neighbor
tissu
morbid
moreov
treatment
suffer
unfavor
complic
includ
implant
adhes
failur
cell
sediment
leakag
address
develop
peptid
hydrogel
capabl
inject
chondrocyt
deliveri
hydrogel
trigger
presenc
cell
allow
homogen
cell
encapsul
physiolog
condit
also
uniqu
abil
shearthin
upon
applic
shear
forc
recov
nearli
origin
rigid
remov
shear
applic
cartilag
repair
use
deliveri
vehicl
scaffold
deliv
cell
minim
invas
manner
object
current
studi
evalu
chondrocyt
respons
phenotyp
genotyp
syring
deliveri
viabil
primari
encapsul
chondrocyt
assess
product
ecm
molecul
examin
histochem
stain
biochem
assay
express
level
cartilagespecif
gene
also
monitor
quantit
pcr
collect
data
suggest
potenti
candid
inject
hydrogel
scaffold
chondrocyt
deliveri
cartilag
repair
advanc
biotechnolog
techniqu
led
rapid
develop
small
protein
antibodi
therapeut
howev
sever
limit
remain
prepar
deliveri
drug
due
suscept
protein
degrad
storag
upon
administr
address
problem
hydrogel
use
deliveri
devic
protein
drug
design
class
peptid
undergo
trigger
hydrogel
respons
physiolog
ph
salt
condit
ph
mm
nacl
peptid
fold
subsequ
selfassembl
form
rigid
hydrogel
stabil
peptid
possibl
control
fold
assembl
kinet
form
hydrogel
differ
rigid
chang
affect
porou
morpholog
within
hydrogel
system
subsequ
influenc
rate
macromolecular
diffus
within
peptid
fibrillar
network
studi
focus
determin
mass
transport
properti
model
protein
hydrogel
protein
vari
molecular
weight
pi
chosen
assess
effect
fibrillar
charg
densiti
hydrogel
mesh
size
releas
properti
network
protein
ad
solut
fold
yield
gel
macromolecul
directli
encapsul
network
nanomateri
explor
assembl
pattern
produc
effect
biosens
optoelectron
catalyt
system
numer
attempt
assembl
gold
nanoparticl
gnp
variou
biomolecul
via
coval
linkag
present
literatur
howev
interact
studi
extens
end
design
system
use
cation
gnp
anion
peptid
facilit
assembl
via
noncoval
interact
anion
variant
leucin
zipper
region
transcript
factor
design
hydrophob
residu
heptad
repeat
remain
unalt
facilit
natur
parallel
dimer
oligomer
peptid
five
solvent
expos
residu
modifi
glu
residu
yield
circular
dichroism
cd
spectroscopi
dynam
light
scatter
dl
transmiss
electron
microscopi
tem
use
character
confirm
assembl
aggreg
gnp
presenc
establish
import
hydrophob
face
cofaci
anion
face
two
control
peptid
scrambl
version
nativ
peptid
also
test
neither
show
evid
facilit
gnp
aggreg
design
system
effect
show
interact
respons
self
assembl
gnp
potenti
futur
applic
work
lie
area
catalyt
system
hydrogel
emerg
biomateri
act
scaffold
tissu
regen
therapi
drug
deliveri
abil
hydrogel
scaffold
temporarili
support
injur
tissu
provid
mechan
properti
consist
tissu
wound
heal
process
allow
optim
tissu
regener
control
degrad
implant
materi
aid
success
integr
new
tissu
form
mani
applic
rate
degrad
hydrogel
scaffold
approxim
rate
new
tissu
format
hydrogel
materi
proteas
hydrolyz
amid
bond
sequenc
specif
manner
could
provid
mean
degrad
hydrogel
tempor
resolut
degrad
profil
peptid
hydrogel
vitro
trypsin
model
enzym
assess
hplc
mass
spectrometri
rheolog
exogen
trypsin
proteolysi
studi
conduct
peptid
gel
respect
fragment
separ
analyt
hplc
character
util
electrospray
ioniz
mass
spectrometri
bulk
materi
properti
assess
oscillatori
shear
rheolog
function
enzym
exposur
time
consist
rate
proteolysi
measur
hplc
mass
spectrometri
result
demonstr
tailor
amino
acid
sequenc
toward
specif
trypsin
use
tune
degrad
peptid
hydrogel
impact
nanotechnolog
medicin
energi
reli
develop
improv
fabric
method
produc
highli
pure
novel
structur
featur
simpl
manner
one
underli
goal
synthet
peptid
scienc
devis
simpl
protocol
program
assembl
kinet
synthet
facil
peptid
desir
size
shape
necessari
surfac
chemistri
lead
nanostructur
pack
hierarch
larger
object
report
recent
effort
design
assembl
small
molecular
peptid
discret
nanostructur
cylind
belt
tube
ribbon
subsequ
assembl
larger
length
scale
highli
order
crystallin
structur
key
featur
design
molecular
structur
motif
altern
hydrophob
hydrophil
amino
acid
sequenc
coval
graft
onto
hydrophob
tail
either
short
alkyl
tail
semiconduct
oligom
explor
applic
regen
medicin
cell
signal
photoelectr
energi
convers
chemic
synthesi
protein
give
exquisit
control
coval
structur
enabl
exampl
incorpor
amino
acid
research
total
synthes
bovin
pancreat
trypsin
inhibitor
bpti
sever
chemic
analogu
appropri
control
undertaken
nativ
chemic
ligat
two
unprotect
peptid
segment
bpti
archetyp
member
serin
proteas
inhibitor
organ
around
short
amino
acid
alphabeta
fold
constrain
three
disulfid
bond
fold
occur
varieti
mammalian
protein
implic
cancer
metastasi
tumor
growth
bpti
mutant
reportedli
destabil
protein
kcalmol
surprisingli
larg
destabil
thought
result
disrupt
unusu
network
interact
involv
amid
gli
explor
effect
substitut
posit
bpti
offer
novel
opportun
look
damp
effect
aromat
ring
flip
subglob
amid
proton
exchang
nmr
properti
uniqu
chemic
analogu
control
molecul
report
converg
synthet
method
greatli
facilit
assembl
peptidesprotein
howev
fundament
drawback
converg
synthesi
epimer
residu
occur
condens
reaction
therebi
limit
contain
either
gli
pro
residu
herein
report
segment
condens
base
isopeptid
method
success
synthesi
bioactiv
peptid
method
allow
use
possess
serthr
residu
segment
condens
without
epimer
serthr
residu
addit
final
deprotect
peptid
effect
purifi
hplc
structur
remark
chang
physicochem
properti
nativ
peptid
final
intramolecular
acyl
migrat
reaction
trigger
nativ
amid
bond
format
neutral
condit
use
method
segment
condens
becom
possibl
posit
bear
gli
pro
residu
suggest
isopeptid
segment
condens
advantag
synthes
larger
peptid
protein
consid
featur
isopeptid
segment
condens
method
would
contribut
field
chemic
synthesi
peptid
protein
sohma
et
al
chem
commun
yoshiya
et
al
tetrahedron
lett
nowaday
peptid
gain
import
treatment
variou
diseas
produc
solid
phase
synthesi
ferment
process
chromatographi
one
import
step
purif
peptid
especi
ferment
process
downstream
process
therefor
chromatograph
step
respons
high
cost
peptid
consequ
chromatograph
process
optim
achiev
maximum
yield
puriti
anoth
import
problem
often
seen
peptid
purif
progress
column
perform
drop
consequ
irrevers
adsorb
impur
restor
separ
perform
clean
place
often
perform
step
involv
wash
stationari
phase
high
ph
solut
remov
irrevers
adsorb
impur
undesir
consequ
clean
place
seen
especi
materi
progress
destruct
stationari
phase
poster
crude
peptid
mixtur
studi
revers
phase
chromatograph
purif
step
optim
lead
best
separ
target
peptid
impur
moreov
effect
clean
place
studi
deterior
purif
perform
chang
stationari
phase
follow
differ
clean
place
step
chemoselect
ligat
use
join
peptid
fragment
togeth
creat
longer
peptid
synthesis
singl
chain
format
linkag
possibl
tool
product
synthet
protein
use
gener
method
import
assess
impact
unnatur
linkag
may
structur
consequenti
activ
biolog
activ
molecul
chemoselect
bond
form
reaction
aldehyd
hydrazin
group
use
assembl
bovin
ribonucleas
mask
aldehyd
amino
alcohol
allow
sequenti
ligat
sever
peptid
fragment
structur
bond
model
within
structur
ribonucleas
molecular
dynam
simul
run
allow
theoret
predict
effect
unnatur
bond
compar
experiment
result
catalyt
activ
enzym
recent
mani
kind
peptid
report
work
synthesi
artifici
lipopeptid
supramolecular
format
studi
first
synthes
hdc
hda
long
alkyl
chain
long
alkyl
chain
consist
hexaethleneglycol
decano
acid
decanamin
next
also
synthes
lipopeptid
hda
hda
use
artifici
amino
acid
deriv
method
synthes
lipopeptid
measur
afm
tem
result
found
synthes
lipopeptid
form
cylindr
micel
detail
investig
discuss
balanc
interplay
amphiphil
properti
grant
antimicrobi
peptid
target
specif
select
toxic
recent
literatur
report
enhanc
peptid
activ
acyl
fatti
acid
differ
length
conjug
peptid
aromat
carboxyl
acid
produc
deriv
structur
resembl
antibacteri
drug
use
anoplin
model
peptid
studi
pyrazinoyl
benzoyl
glycin
residu
hbtuhobtdiea
coupl
would
yield
substitut
pyrazinamid
hippur
acid
carboxamid
deriv
yield
synthet
approach
may
prove
use
prepar
novel
antibacteri
peptid
conjug
drug
mani
natur
occur
monodehydrodkp
possess
biolog
activ
phenylahistin
plh
lead
compound
phase
iii
clinic
trial
us
vascular
disrupt
agent
vda
cyclicdipeptid
monodehydrodkp
use
build
block
templat
combinatori
chemistri
develop
effici
synthet
rout
monodehydrodkp
racem
natur
product
synthesi
previou
studi
focus
work
gladiali
et
al
report
reaction
presenc
catalyt
amount
result
format
dehydroamino
acid
success
appli
method
synthes
monodehydrodkp
reason
yield
racem
present
studi
also
success
expand
method
amino
acid
residu
leu
ser
bzl
case
acid
deriv
use
therefor
method
would
effect
synthesi
natur
product
contain
nicholson
b
hayashi
et
al
drug
gladiali
pinna
g
tetrahedron
asymmetri
although
much
less
known
protein
phosphoryl
signific
protein
sulfat
rapidli
gain
momentum
identifi
crucial
certain
interact
broaden
research
function
tyrosin
residu
within
protein
reliabl
synthes
approach
develop
select
introduct
tyrosin
peptid
still
consid
challeng
acid
labil
aryl
sulfat
ester
acid
deprotect
step
within
contribut
would
like
present
new
select
fmoctbu
spp
approach
introduct
multipl
tyrosin
follow
approach
synthes
sever
repres
part
contain
two
tyrosin
residu
bind
chemotaxi
inhibitori
protein
staphylococcu
aureu
chip
studi
itc
structur
chip
complex
solv
nmr
spectroscopi
clearli
show
import
sulfat
tyrosin
residu
within
bunschoten
et
al
chem
commun
accept
public
haa
et
al
j
mol
bio
chemic
protein
synthesi
crystallographi
use
investig
l
form
recent
discov
snow
flea
antifreez
protein
sfafp
interest
glycin
rich
protein
sequenc
homolog
known
protein
experiment
structur
report
chemic
synthes
l
found
expect
antifreez
activ
ice
recrystal
inhibit
assay
structur
determin
larg
unexplor
approach
call
racem
protein
crystal
found
crystal
format
racem
solut
contain
equal
amount
chemic
synthes
protein
occur
much
readili
alon
facil
crystal
format
also
occur
mixtur
analogu
novel
structur
sfafp
made
six
antiparallel
ppii
helix
wrap
form
compact
bricklik
structur
hydrophil
hydrophob
face
pentelut
bl
gate
zp
tereshko
v
dashnau
jl
vanderkooi
jm
kossiakoff
aa
kent
sbh
j
chem
soc
pentelut
bl
gate
zp
dashnau
jl
vanderkooi
jm
kent
sbh
j
chem
soc
type
repeat
domain
thrombospondin
potent
antiangiogen
activ
structur
interest
fold
make
attract
target
protein
engin
chemic
synthesi
attract
approach
studi
protein
domain
sinc
enabl
use
unnatur
amino
acid
label
detail
analysi
demonstr
first
total
chemic
synthesi
thrombospondin
type
repeat
domain
nativ
chemic
ligat
addit
natur
domain
five
site
side
chain
modif
evalu
two
found
compat
oxid
fold
sever
challeng
encount
peptid
synthesi
due
function
complex
domain
challeng
overcom
use
new
solid
support
scaveng
test
multipl
ligat
site
well
util
combin
spp
individu
peptid
segment
synthet
access
domain
enabl
synthesi
number
variant
contain
arginin
tryptophan
analog
modifi
core
stack
domain
rel
stabil
varaint
investig
via
circular
dichroism
thermal
melt
differenti
scan
calorimetri
provid
insight
stabil
afford
interact
context
nativ
protein
fold
synthes
variant
use
understand
biochem
interact
network
thrombospondin
provid
insight
structur
function
import
protein
domain
grow
interest
develop
design
glycopeptidebas
vaccin
therapeut
stimul
studi
synthesi
although
sever
strategi
glycopeptid
synthesi
develop
repetit
purif
intermedi
still
problem
lower
yield
solid
phase
synthesi
hand
advantag
autom
repetit
coupl
step
drive
coupl
reaction
complet
use
larg
excess
build
block
henc
solid
phase
synthesi
glycopeptid
mani
benefit
yet
strategi
requir
larg
amount
extrem
hard
obtain
therebi
slow
develop
solid
phase
synthesi
glycopeptid
lab
develop
capabl
produc
larg
amount
oligosaccharid
allow
explor
glycopeptid
synthesi
solid
phase
monosaccharid
oligosaccharid
build
block
synthes
appli
glycopeptid
synthesi
differ
resin
determin
effect
resin
type
glycosylamino
acid
coupl
addit
glycosylamin
coupl
strategi
also
explor
strategi
employ
varieti
biolog
relev
glycopeptid
hiv
sequenc
extens
use
peptid
thioester
protein
chemistri
ie
nativ
chemic
ligat
chemoselect
reaction
provid
impetu
search
optim
strategi
synthesi
numer
approach
fmoc
base
spp
publish
method
reliabl
synthesi
peptid
thioester
glycin
establish
howev
fmoc
base
method
synthes
peptid
thioester
chiral
amino
acid
less
reliabl
recent
introduc
novel
method
synthesi
peptid
thioester
glutam
acid
residu
highli
labil
protect
group
first
anchor
solid
support
desir
peptid
assembl
resin
follow
select
remov
glutam
acid
protect
group
dilut
tfa
strong
activ
eg
pybropdiea
nmp
deprotect
carboxyl
acid
result
format
pyroglutamyl
imid
moieti
nucleophil
displac
treatment
thiol
result
releas
thioester
solid
support
present
optim
result
overal
yield
improv
epimer
problem
address
peptid
ligat
valin
report
recent
method
util
penicillinamin
mediat
ligat
reaction
follow
desulfur
give
val
residu
ligat
site
howev
slow
kinet
ligat
step
sever
limit
practic
valu
method
herein
report
thioacid
captur
ligat
overcom
problem
use
ligat
even
junction
compar
studi
use
small
model
peptid
show
thioacid
captur
ligat
exhibit
much
faster
reaction
kinet
nativ
chemic
ligat
use
thioacid
captur
ligat
success
synthes
histon
protein
wherea
attempt
synthes
protein
use
nativ
chemic
ligat
junction
success
christian
haas
h
r
oliv
seitz
nativ
chemic
ligat
valin
angew
chem
int
ed
structur
requir
recognit
complex
polysaccharid
role
interact
differ
cell
organ
remain
unsolv
mani
system
focus
commun
rhizobium
legumin
plant
lead
symbiosi
nitrogen
fixat
main
focu
understand
interact
lipochitin
oligosaccharid
signal
molecul
plant
receptor
predict
interact
withth
lysm
domain
common
protein
moieti
may
gener
peptidoglycan
bind
function
lysm
domain
predict
secondari
structur
two
helic
pack
onto
side
beta
sheet
present
linear
synthesi
lysm
domain
plant
receptor
order
studi
structur
interact
lipochitin
oligosaccharid
signal
molecul
segment
lysm
lysm
domain
receptor
kinas
origin
lotu
japonicu
filicauli
small
protein
rang
size
residu
synthesi
optim
especi
overcom
problem
assembl
end
microwav
heat
use
synthes
key
element
improv
protocol
aspect
synthesi
also
improv
small
protein
subject
variou
condit
fold
disulfid
bridg
format
bind
lipochitin
oligosaccharid
studi
use
rang
biophys
techniqu
homogen
yield
protect
peptid
impedi
chemic
synthesi
protein
fragment
condens
use
epg
exclud
protect
group
method
overcom
issu
examin
synthesi
boc
acm
tbu
tbu
otbu
esterifi
allocholesterol
irradi
react
dipeptid
product
deprotect
purifi
gel
permeat
chromatographi
cycl
repeat
produc
homogen
intermedi
determin
measur
coupl
reaction
kinet
mass
spectrometri
coupl
reaction
minut
littl
uncoupl
amino
compon
could
accur
measur
step
delet
sequenc
compris
approxim
increas
weight
product
obtain
cours
synthesi
remov
allocholesterol
group
readili
effect
high
yield
essenti
homogen
protect
peptid
allow
chemic
synthesi
fragment
condens
becom
biolog
method
protein
product
describ
novel
amid
heptadecapeptid
isol
skin
secret
frog
genu
rana
pipien
saprgcwtk
psk
contain
disulphid
loop
psk
share
high
degre
homolog
core
inhibitori
motif
found
type
proteas
inhibitor
bbi
sunflow
seed
trypsin
inhibitor
asfti
synthet
replic
psk
found
potent
inhibitor
trypsin
ki
slightli
less
nm
valu
fall
determin
asfti
nm
core
inhibitori
loop
bbi
nm
psk
also
exhibit
inhibitori
activ
ki
type
ii
serin
proteas
serin
proteas
involv
tumor
prolifer
compar
favor
degre
inhibit
observ
asfti
ki
bbi
ki
psk
one
first
exampl
natur
occur
inhibitor
could
prove
use
delin
role
proteas
tumour
prolifer
invas
key
word
frog
skin
peptid
proteas
inhibitor
prostat
cancer
type
ii
transmembran
serin
proteas
correspond
author
address
qubacuk
hchen
recent
sever
biolog
activ
peptid
protein
success
pegyl
improv
metabol
stabil
increas
biolog
pegyl
protein
shown
improv
biolog
profil
requir
fewer
inject
counterpart
use
therapeut
goal
work
develop
gener
condit
pegyl
small
protein
eg
thymosin
natur
occur
thymic
peptid
consist
acid
possess
immunomodulatori
activ
use
model
pentapeptid
boc
boc
tbu
condit
optim
pegyl
use
aminoalkyl
procedur
follow
reduct
purif
crude
pegyl
pentapeptid
achiev
dialysi
lyophil
deprotect
boctbuprotect
group
result
expect
posit
ninhydrin
reaction
thymosin
pegyl
coupl
either
aminoalkyl
procedur
use
novel
solvent
place
methanol
maintain
homogen
confirm
structur
provid
hydrolysi
follow
thin
layer
chromatographi
reveal
presenc
amino
acid
present
thymosin
aminoalkyl
procedur
extend
includ
pegyl
grf
grf
biolog
studi
progress
peptid
sequenc
rgd
far
promin
ligand
promot
specif
cell
adhes
integrin
stimul
recent
shown
mutat
rgd
sequenc
fibronectin
rge
sequenc
still
exhibit
bind
affin
although
rge
known
recogn
integrin
howev
fibril
display
slightli
differ
phenotyp
fibronectin
hypothet
model
unexpect
result
propos
curni
et
al
sequenc
fibronectin
repeat
abl
undergo
rearrang
show
activ
less
potenc
mechan
alreadi
known
long
time
wide
consid
process
degrad
act
biochem
clock
limit
protein
lifetim
vivo
curni
et
al
first
show
deamid
process
increas
protein
function
instead
find
stimul
us
creat
librari
cyclic
peptid
contain
isodgr
sequenc
screen
librari
show
variou
new
peptid
high
activ
toward
integrin
receptor
receptor
studi
includ
structur
determin
dock
experi
current
progress
order
elucid
relationship
arrang
biolog
activ
found
cellular
assay
multipl
interact
ppi
govern
function
protein
kinas
c
pkc
famili
isozym
previous
gener
select
regul
peptid
deriv
domain
individu
pkc
isozym
sinc
domain
site
mani
ppi
agonist
antagonist
peptid
regul
use
vitro
vivo
current
test
human
select
antagonist
inhibit
ppi
specif
pkc
rack
agonist
interfer
inhibitori
ppi
within
given
pkc
isozym
caus
activ
inhibitor
activ
regul
cellular
function
mediat
isozym
exampl
show
induc
apoptosi
inhibit
atp
regener
induc
endoplasm
reticulum
stress
induc
cell
adhes
phosphoryl
differ
substrat
compart
current
ppi
inhibitor
inhibit
function
sought
identifi
regul
one
function
regul
potenti
affect
pkc
function
associ
particular
patholog
without
affect
function
ubiquit
enzym
guid
structur
domain
develop
seri
short
peptid
regul
one
peptid
deriv
uniqu
site
induc
transloc
mitochondria
use
myocardi
infarct
model
compon
increas
phosphoryl
subset
substrat
contrast
previou
agonist
induc
transloc
mitochondria
plasma
membran
endoplasm
reticulum
character
new
select
agonist
provid
class
iii
histon
protein
deacetylas
essenti
age
process
report
involv
glucos
metabol
improv
insulin
sensit
repress
furthermor
testifi
laura
bordon
regul
insulin
secret
repress
pancreat
exenatid
use
treat
amino
acid
peptid
shown
experi
exenatid
cell
could
upregul
protein
level
also
gene
express
may
correlationship
previou
result
got
exenatid
could
downregul
protein
level
chronic
pain
neuropath
pain
take
place
due
nerv
injuri
consid
difficult
treat
opioid
often
first
line
treatment
due
side
effect
includ
toler
prolong
treatment
opioid
feasibl
develop
toler
occur
mani
reason
found
opioid
mu
agonist
delta
antagonist
antagonist
reduc
toler
observ
prompt
us
creat
singl
peptid
chimera
could
act
antagonist
delta
receptor
agonist
mu
receptor
made
seri
contain
n
termin
delta
antagonist
pharmacophor
c
termin
pharmacophor
found
mu
delta
affin
seri
increas
length
pharmacophor
decreas
found
optim
ligand
good
affin
constant
ki
mu
delta
receptor
nm
nm
respect
hybrid
molecul
mu
agonist
delta
antagonist
activ
therapeut
advantag
patient
show
respons
current
analges
anticip
new
molecul
show
high
antinocicept
effect
less
develop
toler
less
respiratori
depress
anim
assay
model
support
grant
us
public
health
servic
nation
institut
health
complement
first
line
defens
invad
pathogen
bridg
adapt
immun
howev
inappropri
excess
complement
activ
caus
host
tissu
damag
implic
mani
autoimmun
diseas
includ
alzheim
diseas
rheumatoid
arthriti
macular
degener
amd
sepsi
injuri
transplant
etc
lab
develop
peptid
name
compstatin
abl
select
bind
complement
compon
effect
inhibit
complement
activ
compstatin
analogu
current
phase
clinic
trial
treatment
amd
howev
rel
short
vivo
due
small
size
one
way
improv
peptid
vivo
conjug
molecul
bind
human
albumin
long
day
therefor
design
chimer
peptid
cyclic
albumin
bind
peptid
conjug
either
w
via
short
peg
linker
peptid
synthes
combin
solid
phase
solut
phase
chemistri
avoid
cross
two
disulfid
bond
vitro
assay
show
chimer
peptid
abl
bind
albumin
separ
simultan
thu
chimer
peptid
show
great
promis
longer
vivo
treatment
broader
rang
complement
associ
diseas
preval
obes
increas
alarm
rate
world
wide
need
drug
demonstr
possess
appetit
suppress
potenti
thu
novel
analog
high
select
potenc
potenti
drug
treatment
obes
hypothes
possibl
relat
peptid
hormon
bind
membran
prior
interact
receptor
base
hypothesi
design
novel
analog
increas
membran
bind
segment
residu
pp
fold
famili
peptid
proven
import
receptor
select
taken
advantag
phenomenon
design
two
class
novel
analog
first
segment
replac
differ
amphiphat
sequenc
design
structur
bind
experi
demonstr
high
select
second
differ
segment
deriv
pp
fold
famili
peptid
introduc
e
amin
addit
ly
posit
nativ
sequenc
hypothesi
give
rise
tighter
consequ
make
partli
inaccess
receptor
also
extent
toward
proteas
bind
experi
back
hypothesi
display
interest
yr
affin
dio
mice
studi
show
prolong
efficaci
least
one
analog
viru
like
particl
one
excit
kind
nanoparticl
use
medicin
approach
might
serv
polyval
build
block
provid
stabl
well
character
surfac
use
mani
differ
chemic
reaction
far
particl
success
use
imag
purpos
gain
antibodi
respons
howev
still
suffer
unselect
concern
intern
one
specif
cell
attack
bind
cell
surfac
integrin
constitut
famili
heterodimer
transmembran
cell
adhes
receptor
varieti
extracellular
matrix
protein
eg
vitronectin
fibronectin
pioneer
observ
integrin
especi
hallmark
metastat
cancer
serious
involv
process
tumor
angiogenesi
turn
attract
target
cancer
therapi
two
decad
rgd
sequenc
known
recogn
sever
integrin
eg
report
success
surfac
coat
viru
like
particl
cyclic
integrin
bind
peptid
use
click
chemistri
gain
select
bind
toward
cell
present
integrin
receptor
surfac
integrin
constitut
famili
heterodimer
transmembran
cell
adhes
receptor
varieti
extracellular
matrix
protein
eg
vitronectin
fibronectin
pioneer
observ
integrin
especi
hallmark
metastat
cancer
serious
involv
process
tumor
angiogenesi
turn
attract
target
cancer
therapi
recent
reevalu
integrin
point
import
subtyp
angiogenesi
contrast
assum
far
inhibit
integrin
function
major
challeng
medicin
chemistri
differ
radiolabel
antagonist
investig
angiogenesi
metastasi
vivo
first
radiolabel
antagonist
cyclo
rgdyv
present
r
haubner
et
al
recent
harri
et
al
publish
first
nonpeptid
antagonist
tumor
imag
radiolabel
subtyp
select
ligand
imag
report
literatur
start
recent
publish
integrin
ligand
report
synthesi
first
select
ligand
tumor
imag
applic
new
highli
select
tumor
imag
ligand
entri
inhibitor
peptid
new
class
antiretrovir
drug
treatment
hiv
infect
also
known
fuzeon
enfuvirtid
one
class
approv
fda
although
success
use
treatment
hiv
infect
still
face
mani
challeng
exampl
synthet
peptid
requir
step
costli
low
solubl
neutral
ph
short
human
serum
hiv
strain
resist
report
recent
herein
describ
success
method
express
anoth
hiv
entri
inhibitor
peptid
bacteria
effort
improv
solubl
biolog
activ
chemic
modif
express
peptid
melanocortin
receptor
involv
mani
physiolog
function
includ
pigment
sexual
function
feed
behavior
energi
homeostasi
make
potenti
target
treat
obes
sexual
dysfunct
etc
understand
basi
ligand
receptor
interact
crucial
design
potent
select
ligand
receptor
cyclic
melanocortin
mtii
investig
solut
nmr
spectroscopi
aqueou
solut
dpc
dodecylphosphocholin
use
membran
mimet
environ
nmr
deriv
structur
analogu
dock
within
receptor
act
agonist
antagonist
respect
interest
differ
bind
mode
two
ligand
observ
wide
discuss
detail
structur
inform
complex
obtain
studi
may
assist
futur
attempt
optim
select
potenc
efficaci
agonist
antagonist
receptor
involv
feed
mtii
ac
asp
dphe
arg
trp
ly
ac
asp
dnal
arg
trp
ly
alzheim
diseas
ad
common
neurodegen
diseas
million
peopl
suffer
worldwid
ad
identifi
protein
misfold
diseas
due
accumul
aggreg
amyloid
beta
protein
brain
patient
therefor
compound
select
interfer
aggreg
accumul
desper
need
previou
studi
demonstrta
hydrophob
core
klvff
essent
sequenc
bind
homolog
sequenc
prevent
aggreg
reduc
toxic
vitro
use
multival
variant
klvff
scheper
cowork
demonstr
affin
specif
significantli
improv
strategi
found
effect
prevent
aggreg
nativ
klvff
describ
protein
microsphar
contain
differ
copi
klvff
fragment
surfac
potent
prevent
aggreg
reduc
toxic
cell
microsphar
prepar
ultrason
irradi
variou
protein
bovin
serum
albumin
presenc
differ
amount
klvff
analog
demonstr
microspher
narrow
size
distribut
highli
stabl
differ
condit
moreov
use
confoc
microscopi
fluoresc
label
klvff
analog
show
peptid
present
mainli
surfac
microsphar
intern
volum
fill
differ
contrast
agent
member
egfr
famili
overexpress
breast
cancer
patientsvegf
glycoprotein
contain
structur
inter
intra
chain
disulfid
bond
belong
famili
ligand
class
iii
tyrosin
kinas
growth
receptor
vegf
good
target
cancer
treatment
pertuzumab
bevacizumab
two
human
monoclon
antibodi
mab
target
vegf
respect
overexpress
associ
increas
express
vegf
rna
protein
level
human
breast
cancer
cell
exposur
overexpress
cell
trastuzumab
significantli
decreas
vegf
express
furthermor
posit
associ
vegf
express
breast
cancer
patient
identifi
creat
novel
peptid
molecul
base
known
crystal
structur
complex
pertuzumab
vegf
avastin
potenti
synergi
vegf
inhibitor
want
test
combin
therapi
interact
synergist
addit
manner
kill
tumor
cell
retard
tumor
develop
liang
hyder
endocrinolog
konecni
g
e
meng
g
et
al
clin
cancer
re
neurotox
oligom
amyloid
believ
main
caus
alzheim
diseas
ad
recent
identifi
tetrapeptid
inhibitor
neurotox
show
rescu
inhibit
synapt
activ
character
bind
site
use
tyr
probe
along
sequenc
monitor
chang
intrins
fluoresc
function
bind
addit
perform
relationship
sar
studi
identifi
key
structur
featur
includ
chiral
side
chain
ident
free
control
inhibitori
activ
result
demonstr
despit
small
size
hydrophob
aliphat
natur
four
side
chain
interact
deriv
base
specif
interact
data
serv
basi
design
test
new
peptidomimet
deriv
improv
activ
metabol
stabil
alzheim
diseas
ad
like
caus
neurotox
oligom
amyloid
disrupt
oligomer
promis
approach
develop
therapeut
ad
prepar
seri
fragment
ctf
evalu
bioactiv
identifi
lead
inhibitor
assembl
neurotox
frading
et
al
proc
natl
acad
sci
usa
deciph
mechan
ctf
affect
assembl
neurotox
investig
solubl
secondari
structur
morpholog
interact
ctf
control
fragment
result
demonstr
biophys
properti
ctf
roughli
contrast
inhibit
assembl
neurotox
correl
poorli
ctf
length
understand
relationship
ctf
sequenc
biophysicalbiolog
properti
provid
insight
mechan
action
use
design
test
improv
peptidomimet
inhibitor
toxic
drug
candid
ad
peptid
repres
rich
natur
sourc
potenti
medicin
notabl
pharmaceut
limit
rel
short
durat
action
particularli
good
exampl
phenomenon
peptid
glp
nativ
form
glp
demonstr
extrem
short
plasma
rel
narrow
therapeut
index
notabl
advers
gastrointestin
pharmacolog
explor
set
prodrug
mean
extend
durat
action
broaden
therapeut
index
nativ
hormon
set
dipeptideextend
hormon
analog
synthes
character
chemic
biochem
method
dipeptid
extens
demonstr
much
reduc
vitro
potenc
rel
nativ
hormon
littl
propens
gener
diketopiperazin
dkp
diketomorpholin
dmp
physiolog
condit
analog
prodrug
glp
observ
gener
parent
peptid
cycliz
dipeptid
incub
physiolog
ph
temperatur
rel
rate
dkp
dmp
format
simultan
format
highli
activ
otherwis
chemic
stabl
glp
optim
pharmacolog
use
speed
cleavag
observ
function
conform
propens
dipeptid
extens
resid
cisconfigur
coupl
rel
strength
cycliz
nucleophil
set
glp
prodrug
variabl
identifi
biochem
character
central
insulin
form
residu
crucial
structur
stabil
hormon
biolog
activ
previou
studi
investig
numer
amino
acid
chang
particular
emphasi
natur
amino
acid
report
result
inform
highli
restrict
depth
breath
secondari
structur
chang
explor
given
limit
structur
divers
natur
amino
acid
howev
analog
easier
obtain
sinc
vast
major
prepar
rdna
method
nativ
conform
direct
biosynthesi
nativ
three
disulfid
report
synthesi
biolog
analysi
insulin
analog
select
helix
stabil
element
substitut
aib
residu
salt
bridg
insert
backbon
lactam
cycliz
introduc
posit
facilit
salt
bridg
format
lactam
cycliz
nativ
residu
insulin
analog
synthes
via
chain
combin
procedur
develop
dr
jie
han
report
elsewher
meet
sequenc
depend
synthet
difficulti
encount
lactam
cycliz
step
insulin
analog
demonstr
increas
helic
content
signific
decreas
insulin
receptor
bind
vitro
biochem
signal
observ
analog
seri
one
conclus
set
analog
secondari
structur
alter
specif
site
studi
neg
effect
bioactiv
appear
result
local
alter
conform
aromat
face
region
glucagon
well
recogn
import
achiev
high
affin
interact
respect
receptor
examin
signific
residu
glucagon
amino
acid
scan
posit
perform
basi
studi
observ
relat
similar
aromat
face
glucagon
calcitonin
work
fowler
et
al
human
salmon
calcitonin
variant
stimul
formul
leucin
hypothesi
quest
find
receptor
superagonist
structur
seri
includ
three
natur
aromat
amino
acid
residu
phenylalanin
tryptophan
tyrosin
leucin
posit
peptid
result
illustr
contrast
calcitonin
glucagon
toler
simultan
replac
aromat
charact
leucin
region
specif
residu
found
sensit
chang
studi
posit
peptid
observ
permiss
substitut
observ
bioactiv
chang
subtl
rel
nativ
hormon
result
warrant
addit
studi
explain
clear
differ
recognit
peptid
ligand
calcitonin
glucagon
receptor
well
addit
investig
pertain
degre
structur
chang
toler
residu
fowler
b
poon
muff
r
chiti
f
dobson
c
zurdo
j
pna
glucagon
two
highli
homolog
hormon
involv
mainten
glucos
homeostasi
sizabl
import
clinic
manag
diabet
two
peptid
highli
specif
associ
nativ
receptor
structur
element
within
differ
region
sequenc
confer
biolog
specif
explor
relationship
two
hormon
use
singl
residu
substitut
hybrid
peptid
identifi
set
novel
peptid
exhibit
high
potenc
balanc
glucagon
receptor
modif
glucagon
sequenc
result
nearli
complet
loss
specif
minim
chang
inher
activ
three
modif
nativ
glucagon
addit
amid
produc
peptid
increas
potenc
receptor
potenc
equival
glucagon
signific
increas
potenc
receptor
attribut
increas
alpha
helic
well
enhanc
posit
interact
receptor
high
potenc
repres
refin
set
peptid
vari
select
within
dynam
rang
span
prefer
one
receptor
maintain
full
potenc
one
two
receptor
analog
identifi
provid
basi
investig
vivo
studi
rel
efficaci
safeti
obtain
receptor
purpos
optim
metabol
bodi
weight
protein
prenyl
import
modif
control
subcellular
local
membran
traffick
hundr
human
protein
particularli
belong
ra
rho
famili
prenyl
execut
three
protein
prenyltransferas
farnesyltransferas
ftase
ii
ggtase
catalyz
transfer
cystein
thiol
present
close
protein
ftase
establish
effect
target
develop
cancer
therapeut
bisubstr
enzym
util
protein
substrat
peptid
contain
along
respect
isoprenoid
pyrophosph
catalyt
turnov
bisubstr
inhibitor
design
involv
conjunct
peptid
isoprenoid
fragment
util
cycloaddit
isoprenoid
alkyn
azid
peptid
moieti
peptidotriazol
assembl
chlorotrityl
resin
sequenti
diazo
transfer
click
chemistri
potenc
inhibitor
systemat
modifi
divers
element
aax
motif
linker
length
peptid
triazol
length
isoprenoid
chain
approach
led
discoveri
potent
highli
select
bisubstr
inhibitor
valu
rang
nm
human
immunodefici
viru
type
respons
pandem
infect
world
adult
popul
two
envelop
glycoprotein
play
critic
role
facilit
entri
retrovir
genom
macrophag
third
variabl
loop
consist
amino
acid
play
critic
role
bind
domin
antigen
determin
base
nmr
structur
bound
peptid
antigen
design
synthes
three
constrain
analogu
conjug
epitop
conserv
loop
epitop
conjug
kqiinmwqevgka
crksihigpgrafyttgec
mutant
csihigpgrafytc
gei
mutant
cystin
replac
enabl
cycliz
disulfid
bond
stabil
conserv
region
like
structur
peptid
synthes
use
standard
solid
phase
appli
biosystem
peptid
synthes
cycliz
linear
peptid
perform
use
glutathion
gssggsh
oxid
linear
peptid
final
peptid
recov
homogen
expect
molecular
weight
constrain
peptid
analog
exhibit
strong
bind
broadli
neutral
human
antibodi
immunogen
elicit
stronger
immun
respons
addit
elicit
antibodi
respons
effect
neutral
primari
isol
result
indic
constrain
peptid
use
compon
vaccin
membran
proxim
extern
region
mper
hiv
surfac
glycoprotein
bind
site
sever
broadli
neutral
antibodi
antigen
deriv
region
potenti
import
compon
vaccin
direct
peptid
epitop
antibodi
highli
conserv
steric
obscur
immun
system
intim
associ
viral
membran
presenc
larg
trimer
glycoprotein
spike
order
better
mimic
structur
featur
mper
domain
eye
toward
better
understand
interact
near
membran
peptid
mimic
deriv
hiv
synthes
varieti
structur
chang
affect
characterist
helic
orient
posit
epitop
respect
membran
peptid
mimic
incorpor
membran
bilay
mimic
call
nanodisc
nanodisc
structur
compos
phospholipid
bilay
ring
scaffold
examin
affin
neutral
antibodi
peptid
better
understand
bind
neutral
antibodi
epitop
near
membran
construct
enabl
immun
studi
give
insight
affect
membran
proxim
immun
respons
well
design
simpl
peptid
capabl
stabl
nanodisc
burton
r
antibodi
virus
vaccin
natur
review
immunolog
denisov
g
grinkova
v
lazarid
sligar
g
direct
monodispers
phospholipid
bilay
nanodisc
control
size
j
chem
soc
assess
receptor
bind
affin
analogu
typic
requir
use
number
disadvantag
includ
short
high
cost
need
prepar
prior
use
radioact
safeti
issu
overcom
problem
develop
receptor
bind
assay
initi
label
europium
chelat
free
amino
group
method
label
gave
mixtur
peptid
difficult
purifi
consequ
develop
effici
solid
phase
synthesi
techniqu
prepar
specif
peptid
use
dtpa
chelat
receptor
bind
affin
similar
receptor
bind
affin
pki
determin
use
label
ligand
similar
obtain
use
label
ligand
bind
assay
low
background
highli
reproduc
alzheim
diseas
ad
character
two
major
hallmark
intracellular
aggreg
hyperphosphoryl
protein
pair
helic
filament
extra
cellular
deposit
sever
line
evid
suggest
analysi
especi
might
favor
earli
specif
ad
diagnosi
establish
sensit
polymeras
chain
reaction
base
peptid
contain
two
phosphoepitop
use
immun
obtain
monoclon
antibodi
mab
specif
doubli
phosphoryl
epitop
respect
specif
monophosphoryl
mab
confirm
elisa
immunoblot
histochem
analysi
brain
tissu
ad
patient
thu
mab
combin
detect
csf
low
pgml
rang
digoxigenin
label
detector
mab
assay
optim
detect
limit
pgml
buffer
spike
csf
healthi
individu
achiev
combin
mab
specif
quantif
fourfold
phosphoepitop
singl
phosphoryl
post
mortem
csf
sampl
accomplish
luminesc
ligand
bind
assay
superior
tradit
radiolabel
assay
due
improv
sensit
afford
high
throughput
screen
elimin
use
radioact
accordingli
dissoci
enhanc
lanthanid
fluoroimmunoassay
delfia
technolog
rapidli
emerg
bioanalyt
tool
use
eu
iii
chelat
dtpa
diethylenetriaminepentaacet
acid
howev
delfia
success
use
stabl
chelat
dota
carboxymethyl
due
incomplet
releas
eu
iii
report
modifi
optim
delfia
procedur
use
eu
iii
label
peptid
studi
interact
melanocyt
stimul
hormon
ligand
label
eu
iii
synthes
bind
affin
peptid
cell
overexpress
human
receptor
evalu
use
acid
treatment
protocol
complet
releas
eu
iii
dota
chelat
observ
use
hcl
acid
prior
luminesc
enhanc
step
satur
bind
data
indic
eu
iii
link
peptid
bind
cell
affin
similar
dtpa
analogu
modifi
delfia
procedur
use
monitor
bind
heterobival
peptid
cell
express
msh
cck
cholecystokinin
receptor
support
grant
u
public
health
servic
nation
cancer
institut
arizona
biolog
research
commiss
radioligand
becom
import
tool
diagnosi
treatment
malign
tumor
mani
type
tumor
overexpress
coupl
receptor
regulatori
peptid
make
excel
target
cancer
diagnosi
therapi
vasoact
intestin
peptid
vip
amino
acid
neuropeptid
high
affin
receptor
vip
potenti
radiopeptid
imag
agent
sever
frequent
occur
human
tumor
includ
breast
ovarian
prostat
bladder
pancreat
colon
esophag
carcinoma
found
express
vip
receptor
use
imag
agent
radionuclid
chelat
need
incorpor
peptid
sequenc
stabli
complex
radiomet
ion
dota
acid
often
use
purpos
abl
form
stabl
complex
trival
metal
ion
biolog
system
howev
key
residu
receptor
affin
biolog
activ
vip
distribut
throughout
entir
acid
peptid
sequenc
dota
need
conjug
peptid
posit
interfer
either
receptor
bind
activ
studi
conjug
dota
multipl
posit
within
vip
sequenc
determin
optim
placement
metal
chelat
preserv
receptor
bind
affin
also
studi
effect
dota
conjug
peptid
stabil
stimul
camp
gener
compar
vip
bicycl
octapeptid
potent
inhibitor
eukaryot
transcript
bind
tightli
rna
pol
ii
high
select
polymeras
except
bind
occur
site
polymeras
chosen
use
octapeptid
scaffold
creat
seri
probe
could
use
aid
elucid
variou
transcript
relat
process
specif
prepar
fluoresc
probe
provid
abil
visual
peptid
local
well
enabl
control
transcript
manner
unfortun
poor
cellular
uptak
demonstr
fluoresc
microscopi
render
probe
unsuit
transcript
studi
hypothes
mutat
isoleucin
directli
led
poor
uptak
follow
stereoselect
synthesi
monom
prepar
small
librari
amanitin
probe
vari
ident
amino
acid
studi
effect
cellular
penetr
result
synthesi
probe
well
cellular
uptak
discuss
current
cancer
therapi
exploit
either
differenti
metabol
overexpress
specif
individu
gene
product
aberr
cell
propos
altern
approach
specif
target
combin
receptor
use
heteromultival
ligand
htmvl
heterobival
ligand
htbvl
construct
bind
motif
melanocortin
peptid
ligand
combin
either
cholecystokinin
peptid
ligand
specif
ligand
two
ligand
tether
linker
vari
rigid
length
construct
natur
andor
synthet
build
block
use
lanthanid
base
competit
bind
assay
htbvl
found
bind
higher
affin
appar
cooper
cognat
receptor
compar
monoval
bind
cell
line
transient
receptor
decreas
ligand
system
decreas
ligand
system
bival
bind
mode
label
demonstr
high
avid
specif
heteromultival
target
valid
receptor
combin
approach
approach
crosslink
heterolog
receptor
target
individu
cell
open
new
possibl
specif
target
vivo
theragnost
purpos
support
grant
us
public
health
servic
nci
heterochir
peptid
promis
new
rout
import
compound
use
sensor
smart
materi
catalyst
peptid
contain
amino
acid
period
altern
chiral
exist
natur
gramicidin
polytheonamid
feglymycin
peptid
resid
membran
environ
heterochir
peptid
limit
hydrophob
condit
proper
fold
compar
peptid
contain
acid
heterochir
peptid
differ
structur
peptid
fold
helic
stabil
hydrogen
also
differ
stabil
mechan
instanc
altern
updown
configur
amid
carbonyl
group
along
backbon
result
smaller
absent
macrodipol
helic
overal
dipol
moment
talk
commun
gener
synthet
structur
principl
heterochir
peptid
present
design
synthesi
biophys
character
set
peptid
serin
proteas
thrombin
main
clot
enzym
hemostat
system
addit
effect
platelet
activ
thrombin
two
substrat
coupl
receptor
receptor
par
carri
cryptic
ligand
thrombin
cleav
fragment
reveal
ligand
bind
intramolecularli
activ
platelet
aggreg
thu
develop
direct
thrombin
inhibitor
offer
approach
treatment
myocardi
infarct
acut
coronari
syndrom
modul
hemostat
system
block
thrombu
format
inhibit
clot
platelet
aggreg
previou
studi
shown
pentapeptid
bradykinin
breakdown
product
inhibit
function
thrombin
interact
activ
site
fashion
well
bind
prevent
cleavag
thrombin
studi
led
develop
lead
compound
fm
sequenc
recent
determin
structur
fm
activ
site
thrombin
reveal
potenti
modif
improv
bind
result
two
analog
bg
bg
show
increas
potenc
fm
addit
modif
plan
includ
chang
improv
bioaval
develop
potenti
oral
bioavail
direct
thrombin
inhibitor
structur
studi
integr
membran
protein
imp
often
hamper
difficulti
crystal
environ
altern
nmr
appli
detail
result
far
obtain
analysi
fragment
contain
one
two
tm
domain
studi
structur
dynam
properti
fragment
g
receptor
factor
cerevisia
studi
lppg
micel
trifluoroethanol
water
use
solut
nmr
fragment
consist
residu
domain
first
transmembran
helix
first
cytoplasm
loop
second
transmembran
helix
residu
first
extracellular
loop
nmr
experi
fragment
select
label
specif
amino
acid
proton
select
methyl
group
result
assign
backbon
side
chain
nuclei
media
nmr
investig
reveal
secondari
structur
specif
residu
like
structur
lppg
lppg
structur
consist
result
biochem
experi
identifi
ligand
bind
site
within
region
furthermor
superposit
backbon
atom
model
yield
rmsd
justifi
fragment
approach
toward
determin
full
length
structur
gpcr
studi
insulin
analogu
may
help
provid
better
understand
relationship
insulin
receptor
amino
acid
insulin
especi
involv
recognit
insulin
receptor
particular
residu
also
essenti
insulin
dimer
format
dimer
insulin
import
role
deliveri
hormon
pancrea
circul
administr
insulin
diabet
patient
particular
peptid
bond
insulin
may
result
elimin
abil
form
intermolecular
intramolecular
hydrogen
bond
import
stabil
correct
fold
insulin
monom
dimer
format
interact
receptor
present
sever
novel
insulin
analogu
peptid
bond
posit
determin
bind
affin
analogu
insulin
receptor
rat
adipos
membran
use
isotherm
microcalorimetri
method
compar
energet
dissoci
analogu
insulin
form
dimer
de
octapeptid
insulin
form
dimer
method
allow
us
deduc
sever
clear
conclus
role
individu
peptid
bond
amid
dimer
bind
affin
insulin
ame
pro
one
conform
constrain
acid
particular
torsion
angl
restrict
tran
respect
two
rang
valu
expect
dior
longer
peptid
name
ci
helic
structur
tran
n
ii
structur
work
examin
tendenc
number
dipeptid
type
xxx
xxx
l
aib
l
pro
long
enough
fold
intramolecularli
result
compar
obtain
correspond
dipeptid
base
prototyp
pro
well
known
turn
form
residu
analysi
exploit
diffract
solut
conform
studi
reli
heavili
cd
absorpt
nmr
techniqu
alzheim
diseas
ad
research
low
uncontrol
aggreg
amyloid
peptid
known
caus
difficulti
prepar
monom
result
irreproduc
discrep
outcom
toxicolog
studi
solv
problem
disclos
click
peptid
base
isopeptid
method
peptid
natur
due
isopeptid
structur
peptid
convert
intact
physiolog
condit
via
intramolecular
acyl
migrat
upon
trigger
click
eg
produc
underw
event
start
monomer
random
coil
structur
result
indic
situ
product
monom
click
peptid
use
establish
reliabl
experiment
system
investig
patholog
function
ad
taniguchi
kiso
et
al
j
chem
soc
b
taniguchi
kiso
et
al
chembiochem
c
kiso
taniguchi
sohma
wiley
encyclopedia
chemic
biolog
ed
p
begley
wiley
hoboken
taniguchi
kiso
et
al
chembiochem
press
doi
sohma
kiso
et
al
chem
commun
b
sohma
kiso
et
al
biopolym
pept
sci
human
islet
amyloid
polypeptid
also
known
hiapp
amylin
peptid
major
compon
amyloid
deposit
frequent
found
patient
suffer
diabet
mellitu
type
although
yet
clear
whether
amyloid
deposit
caus
consequ
side
effect
diseas
hypothes
interact
hiapp
cellular
membran
caus
iapp
cytotox
lead
death
provid
insight
interact
cell
membran
iapp
chemic
synthes
human
h
murin
proiapp
well
matur
iapp
miapp
differ
residu
hiapp
known
aggreg
amyloid
deposit
iapp
precursor
synthes
manual
proiapp
prepar
nativ
chemic
ligat
fragment
function
fragment
start
cystein
oxid
fold
purif
yield
iapp
iapp
precursor
amyloid
fibril
format
iapp
combin
thereof
studi
synthet
membran
well
cell
model
develop
describ
protect
effect
iappprecursor
iapp
fibril
format
interest
prepar
novel
probe
studi
interact
delta
opioid
receptor
dor
approach
util
multilabel
peptid
contain
fluoresc
moieti
along
isol
tag
electrophil
affin
label
aid
elucid
specif
dor
amino
acid
bind
peptid
multifunct
peptid
deriv
high
affin
dor
select
antagonist
tipp
tic
acid
multifunct
peptid
success
prepar
fmoc
solid
phase
peptid
synthesi
use
resin
multipl
lysin
residu
bear
differ
side
chain
protect
group
employ
allow
select
deprotect
subsequ
function
side
chain
amin
variou
label
peptid
synthesi
peg
poli
ethylen
glycol
linker
includ
enhanc
water
solubl
separ
tipp
portion
peptid
variou
label
incorpor
interact
peptid
chines
hamster
ovari
cho
cell
express
dor
assess
use
fluoresc
microscopi
experi
provid
evid
novel
peptid
bind
coval
specif
dor
demonstr
util
visual
dor
research
support
nida
grant
long
recogn
chemic
shift
deviat
csd
random
coil
valu
differ
characterist
residu
versu
region
protein
csd
posit
neg
revers
although
rico
earli
advoc
use
shift
qualit
even
quantit
mean
assess
fold
popul
unlik
case
hn
shift
detail
pattern
csd
along
appear
recogn
literatur
yet
protein
mani
amid
unit
two
strand
rang
csd
occur
overlap
narrow
rang
also
appear
discrep
predict
effect
shift
helic
versu
hairpin
answer
question
structur
shift
determin
seri
design
hairpin
vari
fold
stabil
studi
reveal
diagnost
shift
associ
almost
exclus
residu
instanc
aromat
ring
current
effect
csd
larg
secondari
structur
shift
result
search
shift
protein
also
report
test
gener
conclus
base
model
hairpin
protein
agrp
competit
antagonist
melanocortin
receptor
implic
involv
energi
homeostasi
hypothes
disulfid
bridg
hagrp
necessari
bind
activ
propos
interact
interact
use
homolog
model
deriv
agrp
synthes
test
mutant
receptor
determin
uniqu
interact
work
support
nih
grant
wilczynski
wang
xs
joseph
cg
xiang
z
bauzo
rm
scott
jw
sorensen
nb
shaw
millard
wj
richard
ng
luevano
c
j
med
chem
joseph
cg
wang
xs
scott
jw
bauzo
rm
xiang
z
richard
ng
c
j
med
chem
biolog
activ
gpcr
structur
yet
access
analyt
method
human
angiotensin
ii
type
receptor
investig
photoaffin
label
approach
use
angiotensin
ii
drvyihpf
angii
analogu
biolog
accept
photolabil
moieti
mani
contact
point
found
ligand
residu
nevertheless
central
amino
acid
angii
tyrosin
residu
could
never
address
due
inadequ
sar
result
attempt
substitut
remedi
difficulti
dopa
tyr
introduc
posit
angii
maintain
affin
oxid
dopa
moieti
may
form
coval
bond
cystein
residu
target
receptor
trough
michael
addit
free
thiol
oxid
angii
could
thu
label
free
present
immedi
bind
environ
assur
feasibl
analogu
treat
presenc
incorpor
cy
confirm
ms
order
abl
trace
label
receptor
receptor
fragment
angii
perform
confirm
ms
oxid
angii
cy
incorpor
found
therefor
two
pathway
explor
one
angii
streptavidin
hrp
trace
anoth
angii
use
dopa
acetonid
protect
radioiodin
posit
radiotrac
analogu
display
affin
suffici
receptor
analysi
despit
medic
signific
mu
opioid
receptor
mor
play
key
role
mediat
analgesia
littl
known
hysiolog
signific
state
earli
dogma
maintain
mor
like
coupl
receptor
gpcr
function
monom
howev
signific
bodi
evid
report
suggest
gpcr
may
act
dimer
higher
order
oligom
describ
develop
select
fluoresc
peptid
ligand
mor
use
probe
function
monomer
mor
ligand
either
fluoresc
tag
coval
attach
cy
synthes
profil
ligand
establish
cell
express
either
mu
delta
opioid
receptor
well
cho
cell
express
kappa
opioid
receptor
ligand
use
probe
state
yellow
fluoresc
protein
tag
mor
ymor
vitro
forc
monomer
state
use
singl
molecul
fluoresc
tirf
achiev
reconstitut
purifi
ymor
hdl
particl
mimic
lipid
bilay
plasma
membran
monomer
state
forc
limit
diamet
hdl
particl
mor
agonist
dermorphin
use
show
minim
function
unit
mu
opioid
receptor
monomer
addit
novel
method
studi
ligand
bind
monomer
gpcr
vitro
develop
introduct
purpos
matrix
metalloproteinas
mmp
metalloenzym
respons
degrad
extracellular
matrix
differ
type
mmp
matrix
ubiquit
express
almost
everi
type
tumor
cell
undergo
metastasi
object
develop
optim
novel
methodolog
releas
liposom
content
trigger
human
recombin
cancer
cell
secret
purpos
formul
liposom
incorpor
commerci
avail
phosphatidylcholin
major
compon
synthes
cleavabl
conjug
vari
tripl
helic
minor
compon
liposom
encapsul
self
quench
dye
carboxyfluorescein
experiment
method
lipopeptid
synthes
employ
microwav
peptid
synthes
liberti
cem
inc
tripl
helic
peptid
purifi
character
revers
phase
hplc
mass
spectrometri
circular
dichroism
cd
spectrometri
fluoresc
emiss
carboxyfluorescein
liposom
record
spectrophotomet
spectramax
molecular
devic
cell
base
studi
done
use
optim
liposom
formul
human
breast
adenocarcinoma
human
colorect
cultur
cell
line
result
discuss
lipopeptid
synthes
gener
sequenc
gpo
n
gg
peptid
contain
stearic
acid
st
gli
sessil
bond
underlin
vari
gpo
unit
n
n
optim
liposom
formul
obtain
popc
mole
lipopetid
mole
unit
gpo
n
formul
releas
dye
caner
associ
concentr
recombin
human
test
cultur
cell
line
found
metastat
cell
secret
activ
abl
releas
encapsul
dye
cell
secret
much
activ
unabl
show
signific
releas
dye
time
period
conclus
trigger
releas
methodolog
show
signific
promis
releas
experi
cancer
cell
methodolog
next
appli
anim
model
studi
futur
fine
tune
act
drug
deliveri
vehicl
inhibit
express
variou
patholog
condit
investig
grp
play
role
compuls
hindleg
scratch
neck
mice
kappa
opioid
antagonist
gnti
antiprurit
activ
kappa
agonist
nalfurafin
show
gnti
mgkg
sc
behind
neck
elicit
scratch
nalfurafin
mgkg
sc
inhibit
stereotyp
behavior
util
immunohistochemistri
locat
grp
posit
nerv
fiber
epidermi
dermi
mous
skin
superfici
layer
dorsal
horn
spinal
cord
well
grp
posit
small
medium
size
cell
dorsal
root
ganglion
doubl
stain
studi
grp
posit
nerv
fiber
near
cell
express
respons
gnti
inject
locat
later
aspect
superfici
layer
dorsal
horn
cervic
spinal
cord
grp
mrna
level
similar
mice
treat
pretreat
mice
mgkg
sc
grp
receptor
antagonist
markedli
suppress
scratch
conclud
grp
mediat
neither
scratch
antiprurit
activ
nalfurafin
mice
incretin
hormon
involv
regul
glucos
metabol
primari
action
insulin
secret
manner
upon
nutrient
ingest
treatment
type
ii
diabet
receptor
agonist
proven
clinic
benefit
lower
blood
glucos
reduct
bodi
weight
paralog
increas
potenc
extend
physiolog
action
compar
nativ
hormon
peptid
highli
homolog
report
adopt
alpha
helic
secondari
structur
unlik
contain
extens
term
cex
confirm
addit
cex
modestli
improv
camp
induct
engin
report
cell
prepar
analog
incorpor
nativ
residu
result
demonstr
singl
substitut
enhanc
agon
even
absenc
termin
cex
extens
peptid
furthermor
contain
sever
diverg
residu
one
oppos
singl
chang
observ
yield
diverg
result
studi
context
two
differ
hormon
sequenc
demonstr
toler
select
amino
acid
differ
locat
within
region
sequenc
amino
acid
identifi
site
specif
mutat
locat
indic
end
function
link
middl
segment
incorpor
amino
lactam
biolog
activ
peptid
may
restrict
conform
mobil
enhanc
select
increas
potenc
use
novel
strategi
synthesi
peptid
contain
lactam
introduc
peptid
chain
nalkyl
use
cyclic
sulfamid
lactam
annul
microwav
heat
employ
solidphas
protocol
growth
hormon
secretagogu
well
alloster
modul
receptor
furnish
lactam
peptid
biolog
studi
bind
affin
valu
lactam
analog
report
well
inhibit
thymocyt
prolifer
measur
lactam
analog
case
lactam
analog
prepar
exhibit
similar
improv
properti
compar
parent
peptid
presenc
lactam
natur
product
penicillin
well
peptid
analog
enhanc
potenc
greater
receptor
select
underlin
import
synthet
tool
drug
discoveri
particular
insert
lactam
motif
linear
peptid
limit
conform
freedom
stabil
structur
potenti
bioactiv
present
synthesi
peptid
sequenc
perform
solidphas
approach
synphas
lantern
use
cyclic
sulfamid
annul
amino
lactam
residu
onto
peptid
chain
parallel
synthesi
agl
analog
alloster
modul
receptor
rytvela
perform
split
mix
chemistri
lantern
particular
doubl
insert
peptid
sequenc
accomplish
effect
method
combinatori
synthesi
peptid
freiding
rm
j
med
chem
refer
within
perdih
kikelj
curr
med
chem
refer
within
ede
nj
j
immunol
method
quiniou
c
et
al
j
immunol
replic
type
human
immunodefici
viru
hiv
regul
viral
mrna
express
control
hiv
rna
express
complex
involv
interplay
viral
transactiv
sever
cellular
protein
rev
one
protein
rev
protein
essenti
regul
mrna
express
multimer
rev
molecul
bind
throughout
element
rre
promot
export
unsplic
partial
splice
mrna
suggest
multimer
region
rev
two
separ
compris
residu
report
synthesi
mimic
rev
protein
domain
locat
amino
acid
respons
rev
multimer
synthesi
sever
cyclic
peptid
rev
protein
domain
mimic
carri
spp
use
fmoc
strategi
helic
natur
peptid
shown
circular
dichroism
cd
nmr
spectroscopi
fluoresc
reson
energi
transfer
fret
assay
inhibit
also
discuss
use
peptid
drug
pharmaceut
applic
hinder
suscept
enzymat
degrad
proteolysi
low
bioavail
peptidomimet
oligom
addit
methylen
group
backbon
gain
recognit
biolog
pharmaceut
stand
point
consider
resili
proteolysi
metabol
recent
report
two
new
class
deriv
acid
acid
respect
studi
proteolyt
stabil
mix
three
proteolyt
enzym
pronas
trypsin
elastas
well
human
serum
stabil
peptid
compar
evalu
potenti
peptidomimet
peptid
contain
resist
condit
wherea
mix
exhibit
proteolysi
presenc
trypsin
pronas
elastas
rate
degrad
mix
slower
would
expect
featur
import
drug
design
toxic
profil
applic
oligom
design
biolog
activ
peptid
highlight
involv
wide
interact
modul
key
process
would
great
interest
studi
mani
fundament
biochem
pathway
howev
develop
small
molecul
goal
still
challeng
area
research
suitabl
mimet
abl
hold
structur
properli
place
function
group
present
helix
also
easili
synthes
product
number
compound
effici
biochem
studi
recent
report
scaffold
mimic
side
chain
amino
acid
found
posit
simpl
straightforward
synthesi
use
convent
reaction
readili
amen
combinatori
synthesi
thu
report
herein
effici
strategi
synthes
number
librari
construct
involv
sever
repeat
reaction
includ
remov
allyl
ester
amidebond
format
via
acyl
migrat
solid
support
step
carri
high
synthet
yield
facil
effici
approach
allow
product
contain
function
group
repres
hydrophob
eg
ala
val
leu
phe
trp
hydrophil
eg
glu
ly
amino
acid
high
overal
yield
puriti
preterm
labor
signific
medic
social
burden
estim
billion
per
year
usa
highest
per
patient
cost
disord
furthermor
preterm
labor
steadili
increas
last
thirti
year
member
coupl
receptor
famili
prostaglandin
fp
receptor
valid
target
develop
method
prevent
preterm
labor
directli
involv
uterin
contract
onset
labor
potent
alloster
modul
fp
receptor
develop
featur
indolizidinon
dipeptid
mimic
type
ii
surrog
addit
delay
labor
stop
uterin
contract
vivo
mimic
use
vitro
atool
studi
secondari
messeng
signal
fp
bind
receptor
isotop
label
analog
pursu
better
understand
mechan
action
present
discuss
synthesi
biolog
activ
determin
bind
site
novel
alloster
modul
fp
receptor
activ
peri
kg
polyak
f
thouin
e
lubel
wd
chemtob
pct
int
appl
serial
june
overal
balanc
pro
protein
interact
control
suscept
cell
toward
program
cell
death
overexpress
protein
mdmx
associ
chemo
radiat
therapi
resist
nmr
studi
shown
tumor
suppressor
protein
form
amphipath
termin
directli
interact
bind
hydrophob
groov
globular
mdmx
domain
result
inhibit
apoptosi
allow
continu
tumor
growth
synthesi
deriv
mimic
portion
activ
site
capabl
disrupt
interact
could
repres
great
potenti
medicin
chemistri
studi
document
synthes
variou
potent
alpha
helix
mimic
success
bind
activ
site
protein
howev
compound
hydrophob
scaffold
limit
use
drug
present
design
synthesi
new
famili
mimic
base
function
hybrid
scaffold
contain
piperazin
pyrimidin
base
repeat
unit
hold
amino
side
chain
residu
posit
mimic
ith
posit
alpha
helix
novel
scaffold
high
degre
polar
therefor
increas
degre
solubl
potenti
novel
therapeut
compar
previou
mimic
novel
circul
peptid
hormon
produc
testicular
leydig
cell
ovarian
thecal
luteal
cell
male
respons
testicular
descent
foetal
life
suppress
germ
cell
apoptosi
adult
male
wherea
femal
caus
oocyt
matur
antagonist
thu
signific
potenti
clinic
applic
contracept
male
femal
previou
work
shown
receptor
bind
region
larg
confin
central
hormon
conform
constrain
analogu
modest
receptor
bind
antagonist
activ
employ
evalu
sever
approach
increas
peptid
order
better
present
key
receptor
bind
residu
increas
affin
receptor
analogu
higher
gener
higher
receptor
bind
affin
although
structur
consider
limit
effect
method
rapid
sequenc
determin
peptoid
oligo
glycin
hybrid
select
combinatori
librari
develop
method
bead
carri
uniqu
peptoid
sequenc
subject
multipl
cycl
partial
edman
degrad
ped
treatment
molmol
mixtur
phenyl
isothiocyan
pitc
chloroform
gener
seri
truncat
product
peptoid
ped
fmoc
group
remov
react
side
chain
via
piperidin
treatment
result
mixtur
peptoid
truncat
product
analyz
laser
desorpt
ioniz
maldi
mass
spectrometri
reveal
sequenc
peptoid
rapid
sensit
inexpens
sequenc
method
greatli
expand
util
combinatori
peptoid
librari
biomed
materi
research
reticular
network
within
lymph
node
conduit
system
form
infrastructur
fast
deliveri
solubl
substanc
affer
lymph
lumen
high
endotheli
venul
hev
conduit
associ
dendrit
cell
dc
capabl
take
process
solubl
antigen
directli
fish
nanomet
size
conduit
transport
affer
lymph
data
current
avail
antigen
composit
human
lymph
avail
resid
dendrit
cell
constantli
sampl
repertoir
studi
report
import
sequenc
inform
peptid
human
lymph
healthi
donor
use
advanc
proteom
approach
high
resolut
electrospray
ioniz
mass
spectroscopi
sequenc
togeth
protein
msm
databas
search
use
mascot
sequest
algorithm
abl
sequenc
three
hundr
peptid
present
lymph
signific
major
peptid
deriv
vivo
process
turnov
extracellular
matrix
protein
collagen
laminin
fibronectin
mucin
sequenc
peptid
screen
potenti
affin
mhc
class
ii
protein
use
algorithm
best
hit
candid
screen
found
high
bind
affin
either
mixirin
b
c
recent
isol
marin
bacillu
sp
bacterium
shown
cytotox
activ
human
colon
tumor
cell
mixirin
subsequ
identifi
mixtur
cyclic
lipopeptid
belong
iturin
class
compound
iturin
contain
proteinogen
acid
residu
one
unusu
lipophil
acid
residu
undetermin
absolut
stereochemistri
acid
moieti
mixirin
b
synthesis
enantioselect
novel
acid
homolog
procedur
yield
enantiom
acid
residu
lipophil
acid
suitabl
protect
subsequ
fmoc
spp
four
novel
potenti
anticanc
compound
synthesis
techniqu
mixirin
acid
epim
mixirin
b
acid
epim
synthesi
evalu
report
crambin
possess
import
salt
bridg
side
chain
guid
format
correct
disulfid
bond
contribut
tightli
fold
overal
set
use
chemistri
replac
salt
bridg
coval
bond
led
us
ask
artifici
coval
bond
allow
molecul
fold
correct
disulfid
bond
format
replac
salt
bridg
amid
bond
never
done
protein
possibl
total
chemic
synthesi
result
novel
topolog
fascin
polypeptid
chain
start
end
novel
topolog
reminisc
ident
natur
occur
cyclotid
lasso
protein
chemic
synthesi
uniqu
topolog
analogu
highli
challeng
devis
effici
converg
synthet
rout
protein
novel
topolog
synthet
challeng
repres
protein
molecul
novel
topolog
led
develop
kinet
control
ligat
use
novel
crystal
crystal
synthet
topologu
determin
molecular
structur
crystallographi
structur
reveal
novel
topologu
share
fold
similar
nativ
crambin
correct
disulfid
bond
format
even
presenc
artifici
coval
bond
replac
salt
bridg
bang
phd
thesi
chapter
bang
pentelut
b
l
kent
sbh
angew
chem
int
ed
pentelut
b
l
gate
z
p
tereshko
v
dashnau
j
l
vanderkooi
j
kossiakoff
kent
b
h
j
chem
soc
acid
gla
incorpor
peptid
mimic
domain
natur
occur
protein
incorpor
unnatur
amino
acid
residu
peptid
use
peptid
synthesi
spp
quit
costli
motiv
mani
research
group
develop
synthes
residu
contain
correct
group
necessari
spp
herein
ester
synthes
easili
prepar
racem
amino
acid
ester
precursor
resolv
use
papain
approach
begin
protect
amin
glycin
methyl
ester
subsequ
coupl
methylenemalon
via
michael
addit
acid
hydrolysi
imin
follow
enzymat
resolut
use
papain
provid
enantiomer
pure
amino
acid
suit
succinimid
econom
synthesi
simpl
start
materi
provid
fulli
protect
unnatur
amino
acid
residu
suitabl
use
peptid
synthesi
